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Fluctuations in the relative concentrations of proteins in non-stimulated cells 
can lead to aberrant signaling. In a novel interaction, the SH3 domain of Plcγ1 
competes with the SH3 domain of Grb2 for binding to FGFR2 in a 
concentration-dependent manner. Consequently, reduction of cellular 
concentrations of Grb2 lead to receptor-dependent recruitment of 
unphosphorylated Plcγ1. Bringing of the phospholipase to the membrane in this 
way upregulates its activity, resulting in increased PIP2 turnover to IP3 and DAG 
resulting in elevated cellular calcium levels. These signaling events increase 
cell migration and invasion. A further consequence of the depletion of PIP2 is 
the inhibition of PTEN phosphatase activity. Inhibition of PTEN activity leads to 
the accumulation of PIP3, which recruits Akt leading to its phosphorylation and 
activation. Therefore, depletion of Grb2 indirectly leads to activation of the 
proto-oncogene Akt inducing phenotypic alterations characteristic of 
tumorigenesis including anchorage-independent cell growth and tumor 
formation in mice models. 
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Chapter One: Introduction 
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FGFR signaling and its role in cancer 
Fibroblast growth factor (FGF) signaling mediates and controls many 
physiological functions. The FGF family is composed of 18 different ligands that 
act through 4 conserved receptor tyrosine kinases (RTKs): fibroblast growth 
factor receptor (FGFR) 1, FGFR2, FGFR3, and FGFR4 (Fig 1.1). A fifth 
receptor, FGFR5, is known to negatively regulate signaling even though it lacks 
a tyrosine kinase (TK) domain. FGFs are secreted glycoproteins that are 
sequestered via heparan-sulfate proteoglycans (HPSGs) to the extracellular 
matrix or cell surface. Heparinases, FGF binding proteins, and proteases 
release FGFs allowing them to bind to HPSGs (Fig 1.1). The specificity of the 
ligand-receptor interaction is mediated by FGFR alternative splicing and tissue 
specific expression of both FGFs and FGFRs (1). 
FGFRs rely on ligand-dependent dimerization (1) or protein-dependent 
dimerization, as is the case for FGFR2 (2). Dimerization causes a 
conformational change that activates the intracellular kinase domain, resulting 
in the trans-phosphorylation of the intracellular tail and TK domains. 
Phosphorylated tyrosine residues on the receptor provide binding sites for 
downstream effectors allowing for a cascade of downstream signals to occur, 
ultimately influencing mitogenesis and differentiation (1).	   
In the absence of extracellular stimulation, FGFR2 binds to the C-terminal Src 
Homology 3 (SH3) domain of growth factor receptor-bound protein 2 (Grb2) 
(2,3). The Grb2 dimer recruits two molecules of FGFR2 to form a 
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heterotetramer. In this state ‘background' receptor kinase activity is limited to 
the phosphorylation of tyrosine residues (Y) 653 and 654 in the activation loop 
of FGFR2. Furthermore, the receptor is unable to recruit downstream effector 
proteins or initiate signal transduction. Upon extracellular growth factor 
stimulation, FGFR2 dimerization is stabilized, leading to the upregulation of 
autophosphorylation. Full activation of the receptor induces phosphorylation of 
Grb2 on Y209. This results in the release of Grb2, thus allowing other 
downstream proteins to be recruited to FGFR2 (Fig 1.2). 
 
 
Fig 1.1 FGFR structure and control of ligand specificity. a) The structure of 
the FGFR complex comprises two receptor molecules, two FGFs, and one 
HSPG chain. FGFs bind to cell surface HSPGs with low affinity and to FGFRs 
with high affinity. FGFRs are composed of three extracellular immunoglobulin 
(Ig) domains, a single transmembrane helix, and an intracellular split tyrosine 
kinase (TK) domain. The second and third Ig domains form the ligand-binding 
pocket and have distinct domains that bind both FGFs and HSPGs. Ligand-
binding specificity is generated by alternative splicing of the Ig III domain. The 
first half of Ig III is encoded by an invariant exon (IIIa), which is spliced to either 
exon IIIb or IIIc.b) FGFR2-IIIb and FGFR2-IIIc ligands are shown in orange and 
green, respectively. 
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Fig 1.2 Model of the molecular mechanism of Grb2-mediated activation of 
FGFR2. Dimeric Grb2 (SH3 domains—red; SH2 domain—yellow) is bound via 
its C-SH3 domain to the C-terminal region of FGFR2 (blue), resulting in the 
formation of a 2:2 heterotetramer and receptor predimerization. The kinase 
domains of FGFR2 (blue ovals) permit the phosphorylation of Y653 and Y654. 
The binding of FGF (orange) and HSPG (red line) to FGFR2 induces a 
conformational change that results in Grb2 phosphorylation by the FGFR2 
kinase domain. Phosphorylated Grb2 is released from the receptor. FGFR2 
kinase domains become fully activated and transphosphorylate tyrosine 
residues formerly buried in the Grb2-receptor interface (adapted from Lin et al., 
2012 with permission from Cell). 
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In addition to Grb2, many other adaptor proteins bind to FGFRs. For example, 
fibroblast growth factor receptor substrate 2 (FRS2) binds to the 
juxtamembrane region of FGFRs through its phosphotyrosine binding (PTB) 
domains. Phosphorylated FRS2 can recruit son of sevenless (SOS) and in turn 
activate the mitogen activated protein kinase (MAPK) pathway. FGFRs can 
directly or indirectly (via adaptor proteins) activate four pathways: rat sarcoma 
(RAS)/ rapidly accelerated fibrosarcoma (RAF)/MAPK, phosphatidylinositide 3-
kinase (PI3K)/-AKR mouse T-cell lymphoma protein (Akt; protein kinase B), 
signal transducer and activator of transcription (STAT), and phospholipase Cγ1 
(Plcγ1) (1). 
The significance of FGFR signaling in tumorigenesis was shown by a screen of 
1000 somatic mutations in the coding exons of 518 protein kinase genes in 210 
cancers (4). For example, bladder cancer has a well-established link to FGFR 
mutations. FGFR2 mutations, which are usually extracellular and equal to the 
activating germline mutations found in craniosynostosis syndromes, have been 
found in 12% of endometrial carcinomas (5). Endometrial cancer-derived cell 
lines are sensitive to FGFR tyrosine inhibitors,which reflects oncogenic 
addiction to mutant-activated FGFR. 
Protein recruitment to activated FGFR2 usually occurs via the C-terminal region 
of the receptor. C-terminal sequence splicing leads to the derivation of a major 
group of isoforms. One should note that perturbation of the amino acid 
sequence in this region might have pathogenic and tumorigenic outcomes. For 
example, point mutations in the C-terminal region of FGFR2 have been linked 
	   6	  
to melanoma (6), and deletions of the C-terminal sequence, which are found in 
a majority of human breast carcinoma cells, have enhanced transforming 
activity (7,8). Deletions in the FGFR2 C-terminal sequence are also found in 
bladder, stomach, and gastric cancers (9-12).  
Grb2: Function and importance 
Grb2 is a ubiquitously expressed adaptor protein that is generally considered to 
play a passive role in RTK signaling because it does not possess intrinsic 
enzymatic activity. Grb2 consists of a Src Homology 2 (SH2) domain 
sandwiched between N and C-terminal SH3 domains (Fig 1.3). The SH2 
domain binds phosphorylated tyrosine residues on docking proteins or 
receptors. The N and C-terminal SH3 domains recognize proline-rich sites on 
proteins, such as SOS (13), or receptors, such as FGFR2 (2). 
Grb2 is critical for the regulation of mitogen-independent FGFR2 heterotetramer 
formation (2) and inhibits tyrosine-protein phosphatase non-receptor type 11 
(PTPN11 or Shp2)-mediated FGFR2 activation loop tyrosine dephosphorylation 
(3). Thus, evidence indicates that Grb2 is not a passive adaptor protein but 
rather a fundamental positive and negative regulator of FGFR2 phosphorylation 
and downstream signal transduction (3). 
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Fig 1.3 Grb2 domains. Grb2 consists of one phosphotyrosine (pY)-binding 
SH2 domain sandwiched between two proline rich motif-binding SH3 domains. 
 
 
Plcγ1: Function and importance 
Mitogen-induced stimulation of various cell surface receptors activates the 
cytoplasmic lipase phospholipase C gamma (Plcγ). The two Plcγ isoforms 1 
and 2 act downstream of receptors with and without intrinsic TK activity. The 
Plcγs are unique amongst the phospholipases in having the split phospholipase 
domain separated by functional domains. The catalytic domain of 
phospholipases is composed of X and Y boxes, which are two sequentially 
discrete regions separated by an extended linker region (X/Y linker).The X/Y 
linker includes sequentially a split PH domain, two SH2 domains (NSH2 and 
CSH2, respectively) and an SH3 domain (Fig 1.4). Activated Plcγ1 hydrolyzes 
the membrane lipid phosphatidylinositol 4,5-bisphosphate (PI[4,5]P2 or PIP2) to 
form inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mediates 
Ca2+ mobilization, whereas DAG activates protein kinase C (PKC) signaling.  
Plcγ1 activation requires membrane translocation. Plcγ1 is phosphorylated on 
four main tyrosines: 472, 771, 783, and 1254. Phosphorylation on Y783 has 
been reported to be required for Plcγ1activation. 
 
Y209	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Fig 1.4 Plcγ1 domains. Schematic illustration of the sequence of Plcγ1 
domains. PH: pleckstrin homology domain. EF: EF-hand calcium-binding 
domain. X and Y: catalytic domains. P and H: split PH domain. NSH2 and 
CSH2: N-terminal and C-terminal Src homology 2 domains. SH3: Src 
homology-3 domain. C2: protein kinase C conserved region 2 domain.SH2 
(yellow) and SH3 (red) domains shown as circles. 
 
 
Plcγ1 phosphorylation on Y1254 was shown to be required for maximal growth 
factor-induced stimulation, whereas phosphorylation on Y771 was proposed to 
act as a negative regulator. Some studies have also shown that 
phosphorylation of both Y775 and Y783 play equally important roles in 
Plcγ1activation (14).  
Other studies and as shown in Fig 1.5  reported that the catalytic domain of this 
lipase is inhibited by its CSH2 domain. Upon stimulation, NSH2 domain binds to 
the receptor leading to receptor-mediated Plcγ1 phosphorylation on Y783. This 
consequently induces a conformational rearrangement that releases the 
autoinhibition of the enzymatic activity(15). 
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Fig 1.5 Mechanism for phosphorylation-dependent Plcγ1 activation. In the 
non-stimulated state, the catalytic domain (red cylinder) of Plcγ1 is auto-
inhibited by the CSH2 domain (yellow cylinder). Receptor activation provides a 
pY (green dot) docking site for the NSH2 domain (yellow cylinder) of the lipase, 
resulting in its translocation to the plasma membrane for site-specific tyrosine 
phosphorylation by RTKs. Tyrosine phosphorylation of Plcγ1 induces direct 
interactions with the CSH2 domain. Engagement of the CSH2 domain by 
phosphorylated tyrosine induces structural rearrangements of the CSH2 domain 
with respect to the catalytic domain, leading to the release of auto-inhibition. 
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Plcγ1 has many important functions in the intracellular transduction of receptor-
mediated tyrosine kinase activators. It is also considered to be critical in 
mediating metastasis. Tumor metastasis is the ability of cancer cells to spread 
from a primary site and form tumors at distant sites. It is a multistep process 
that involves local invasion, followed by intravasation and survival, 
extravasation, initiation, and maintenance of micrometastases at distant sites, 
and vascularization of resultant tumors (16) (Fig 1.6). Cell motility and invasion 
play an indispensable role in metastasis; therefore, identification of involved 
proteins and characterization of the underlying mechanisms regulating cell 
motility are essential to understanding metastasis development. 
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Fig 1.6 A schematic of the metastatic process a) An in situ cancer 
surrounded by an intact basement membrane. b) Invasion requires changes in 
cell–cell and cell–extracellular matrix adherence, destruction of proteins in the 
matrix and stroma, and motility. Metastasizing cells enter distant tissues by 
means of c) the lymphatics (pink oval) d) the circulation (red ovals represent 
endothelial cells). e) This is followed by survival and arrest of tumor cells and 
extravasation from the circulatory system. Metastatic colonization (here in the 
lungs) occurs through single cells, which can develop into angiogenic 
metastases. 
 
 
Directed cell migration is regulated by growth factors and chemokines that bind 
and activate specific receptors, such as RTKs, which activate cytoskeleton 
rearrangement and cellular motility via a network of signaling pathways. 
Activated Plcγ1 plays a decisive role in both cytoskeletal changes and migratory 
ability associated with the metastatic process. Plcγ1 is highly expressed in 
metastatic colorectal cancer and breast carcinomas. Plcγ1 is critical for breast 
cancer cell migration and invasion, and down-regulation of its lipase activity has 
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been shown to inhibit the metastasis of human MDA-MB-231 breast cancer 
cells to lung in an in vivo mouse model (17). However, the mechanism by which 
this lipase induces metastasis or the domains involved require further 
investigation. 
 
PTEN: Function and importance 
Phosphatase and tensin homolog (PTEN) is a phosphatidylinositol phosphate 
(PIP) phosphatase specific for the 3-position of the inositol ring. PTEN has been 
shown to have activity towards PIP, PI(3,4)P2, and phosphatidylinositol (3,4,5)-
triphosphate (PI(3,4,5)P3 or PIP3) in vitro. However, PIP3 is the most important 
substrate in vivo (Fig 1.7). PIP3 (generated by PI3K via the phosphorylation of 
PIP2)  provides a binding site  for many PH domain-containing signaling proteins 
such as Akt and 3-phosphoinositide dependent protein kinase-1 (PDK1). Thus, 
PTEN via PIP3 can affect a large variety of physiological processes in both 
developing and adult organisms. PIP3 is best known for its promotion of cell 
proliferation and survival by inducing phosphorylation and activation of Akt 
kinase.  
PTEN is involved in several pathological processes and is inactivated or deleted 
in many tumor types where the frequency of tumor-associated mutations rivals 
that of the p53 tumor suppressor (18). Indeed it is considered to be the second 
most highly mutated oncogene.  
The substrate of PTEN, PIP3, is important in chemotaxis. During chemotaxis, 
PIP3 localizes sharply to the leading edge of the cell to regulate the direction 
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and formation of pseudopods at the cell anterior. Such an effect, however, also 
requires PIP2-regulated localization of PTEN to the cell posterior (19). 
PTEN is regulated by numerous molecular mechanisms generating a 
continuum of functional PTEN levels in sporadic cancers and inherited 
syndromes. PTEN function can be compromised by genetic mutations, which 
result in a heterozygous loss (50%) or a homozygous loss (100%) of function. 
In addition, several PTEN-interacting proteins can either positively or negatively 
regulate PTEN function. Furthermore, disruption of competing endogenous 
RNA (ceRNA) networks, epigenetic silencing, transcriptional repression, 
microRNA (miRNA) regulation, post-translational modifications, and aberrant 
localization can lead to subtle or significant changes in PTEN function (20). 
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Fig 1.7: PTEN/PI3K/Akt pathway. PTEN opposes PI3K function to inactivate 
Akt signaling. Following PTEN loss or down-regulation the resulting 
accumulation of PIP3recruits the pleckstrin homology (PH) domain-containing 
proteins Akt and PDK1 to the membrane. Akt is then activated by 
phosphorylation at threonine 308 (T308) by PDK1 and phosphorylation at 
serine 473 (S473) by PDK2 (mTORC2; composed of mammalian target of 
rapamycin [mTOR], DEP domain-containing mTOR-interacting protein 
[DEPTOR], target of rapamycin complex subunit LST8 [mLST8], mammalian 
stress-activated protein kinase interacting protein 1 [mSIN1], proline-rich protein 
5 [PROTOR], and rapamycin-insensitive companion of mTOR [RICTOR]). At 
the membrane, association with carboxyl-terminal modulator protein (CTMP) 
prevents Akt phosphorylation and hence, its full activation. Phosphorylation of 
CTMP results in the release of Akt and its subsequent phosphorylation. 
Activated Akt drives cell survival, proliferation, and cellular metabolism through 
inhibitory/activatory phosphorylation of downstream proteins.  
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Akt: Function and importance  
Akt is a serine/threonine kinase that was originally identified as a homologue of 
the v-Akt oncogene from a transforming retrovirus in a spontaneous thymoma 
of a mouse. There are three members of the Akt family (Akt 1, Akt 2, and Akt 3) 
with certain isoform-specific features. On PI3K activation, the PH domain of Akt 
binds to PIP3. This leads to the phosphorylation of Akt at threonine 308 and 
serine 473 and its full activation(Fig 1.7). 
Activated Akt regulates multiple processes, such as cellular proliferation, 
apoptosis, and glucose metabolism, through its well-characterized downstream 
effectors. Akt can be inactivated by CTMP which binds to Akt preventing its 
phosphorylation and downstream signaling. Moreover, overexpression of CTMP 
can reverse the phenotype of v-Akt-transformed cells (Fig 1.7). Akt is also 
regulated by its association with heat shock protein 90 (HSP90), which protects 
it from protein phosphatase 2A (PP2A)-mediated dephosphorylation (21,22). 
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Chapter Two: SH3 domains of Grb2 and Plcγ1 
compete for the same binding site on FGFR2 
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Background 
Recently, Grb2 has been shown to form a kinase-active heterotetramer with two 
molecules of FGFR2 in non-stimulated cells (2, 3, 23). This causes the 
phosphorylation of activation loop tyrosine residues, which is inadequate to 
cause downstream activation of signaling pathways. Grb2 binds FGFR2 
through its C-terminal SH3 domain; therefore, this protein complex formation 
occurs independently of growth factor stimulation and tyrosine phosphorylation. 
Thus, Grb2 can prevent aberrant downstream signaling by acting as a 
concentration-dependent control protein.  
The physiological importance of maintaining an elevated Grb2 concentration is 
highlighted through database analysis (Fig 2.1). Database analysis showed that 
FGFR2-expressing tumor tissue samples with low concentrations of Grb2 
display concomitant high expression levels of another FGFR2 ligand, Plcγ1. 
Low Grb2 expression and increased expression of Plcγ1 have been linked with 
the metastatic potential of many types of cancers. Therefore, investigation of 
the molecular basis of this inverse relationship between Grb2 and Plcγ1 protein 
concentrations and its effect on metastatic outcome is likely to be highly 
important. 
To investigate this relationship one should understand the function and 
molecular basis of activation of both proteins. Upregulation of Plcγ1 activity 
usually occurs when the NSH2 domain of Plcγ1 binds to a cognate site on 
FGFR2 (pY769; 24-26). Once bound to the receptor, Plcγ1 becomes 
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phosphorylated on several tyrosine residues, including Y775 and Y783, within 
the X/Y linker region (27,28). This is followed by the intramolecular binding of 
CSH2 to pY783 which activates the Plcγ1 by inducing a gross conformational 
change that releases the auto-inhibition (15,29-31). Access to plasma 
membrane-embedded phospholipids is facilitated by the binding of the N-
terminal PH domain to PIP3 (32).  
On the other hand, the ubiquitously expressed adaptor protein,Grb2, which 
does not possess enzymatic activity, is involved in numerous RTK signaling 
events. This protein is best known for its role in linking activated RTKs to the 
guanine nucleotide exchange factor SOS to upregulate the downstream MAPK 
pathway in growth factor-stimulated cells. Also, Grb2 is critical in forming a 
stable heterotetramer with FGFR2, thus maintaining homeostasis in non-
stimulated cells (2,23). Upon FGFR2 stimulation, Grb2 is phosphorylated and is 
released from the receptor. Thus, it plays a dual regulatory role in FGFR2-
mediated signaling in stimulated and non-stimulated cells.  
RTK-mediated signal transduction is initiated through provision of cognate, 
phosphorylated binding sites to downstream signaling targets by the action of 
growth factor-dependent up-regulation of the receptor kinase. This mechanism 
represents a level of control that is imposed by the requirement of specific 
kinase phosphorylation precluding the effects of random binding events and 
fluctuation of local protein concentrations. Here, we demonstrate that Grb2 
constitutively controls the stimulation-independent recruitment of Plcγ1 to 
FGFR2 and its subsequent membrane localization and activation through direct 
	   19	  
inhibition of a mutual binding site on the receptor. Therefore, this interaction is 
dependent on protein concentration and relative equilibrium binding constants 
and not phosphorylation status of the proteins of interest.  
 
Figure 2.1 Metastatic potential is dependent on expression levels of Plcγ1 
and Grb2.The Grb2 expression level in cancer cell lines was based on data 
extracted from Gene Expression Omnibus (GEO) website (accession number: 
GSM127198). The heat map was generated using the R Console Statistical 
Program. The data shown only includes 20 cell lines out of 60 cells lines used in 
the original proteomic-based profiling. Cancer types were chosen based on the 
expression of FGFR2 and ability to form macrometastasis. Adherent cell lines 
were selected for compatibility and comparability with the focus of this work; 
therefore, central nervous system cancer cell lines, leukemic cell lines, and 
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melanoma cell lines were not included. Cell lines were classified as having high 
relative metastatic potential (H) or low relative metastatic potential (L) based on 
extensive literature search. Plcγ1 and FGFR2 expression levels in tissues were 
extracted from thehttp://www.proteinatlas.org/website and verified by literature 
search. The percentage of protein expression in the tissues was based on the 
level of antibody staining, which can be found in the “Cancer Tissue Summary” 
provided by the website. 
 
Methods 
Cells 
Human embryonic kidney 293T (HEK293T), and human squamous carcinoma, 
A431 epidermoid carcinoma were maintained in Dulbecco’s modified Eagle’s 
high glucose medium (DMEM). DMEM was supplemented with 10% (vol/vol) 
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Lonza) in a humidified 
incubator at 37°C with 10% CO2. HEK293T cells stably expressing FGFR2 with 
a C-terminal GFP fusion (FGFR2-GFP) were produced as previously described 
and used throughout except in stated experiments in which parental cell lines 
were adopted (45). Grb2 (G2i), and Plcγ1 (Pγi) knockdown cells were 
generated by infecting cells Grb2 shRNA and Plcγ1 shRNA lentiviral particles, 
respectively, followed by selection with 7 µg/ml puromycin. Controls cells (Ci) 
were infected with scrambled shRNA lentiviral particles. Knockdown of Grb2 
and Plcγ1 in surviving cells was confirmed by western blot. Cells were serum 
starved overnight prior to stimulation with FGF9 for 30 min. 
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Molecular Cloning 
Truncated Plcγ1 polypeptides SH223 (residues 550-848) and SH3 (residues 
795-848) were made. For SH223, individual point mutations (R586A and 
R694A) were generated in NSH2 and CSH2. Tyrosine mutants and double 
mutants (DM) were generated from full-length human influenza hemagglutin 
(HA)-tagged Plcγ1. Three individual point mutations were generated in a GST-
tagged polypeptide corresponding to the very C-terminal 58 amino acids 
(P804A, P810A, and P813A). The kinase dead cytoplasmic portion of FGFR2 
(residues 413-821) was generated through a point mutation (K517I).  
 
Protein Expression and Purification 
6Xhistidine, glutathione S-transferase (GST), HA, green fluorescent protein 
(GFP), and red fluorescent protein (RFP)-tagged full-length and truncated 
constructs of FGFR2, Grb2, and Plcγ1 were expressed and purified from E.Coli 
as previously described (28).  
For protein purification, the constructs of interest were transformed into 
competent cells. LB media (1 L) with 50 µg/ml antibiotic (ampicillin or 
kanamycin) was inoculated with10 ml transformed cells. The culture was grown 
to an OD600 cell density of 0.6 at 37°C with constant shaking. The temperature 
was dropped down to 20°C before the addition of 300 µM IPTG for the induction 
of protein expression. After a 12-h growth period, the cells were harvested by 
centrifugation, resuspended in purification buffer (50 mM Tris lysis buffer pH 
8.0, 100 mM NaCl, 1 mM β-mercaptoethanol, and protease inhibitors),  
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sonicated, and centrifuged (20,000 x g) for 45 min at 4°C. The pellet was 
removed, and the filtered supernatant (cleared extract) was applied to an affinity 
column equilibrated with purification buffer. Proteins were eluted from the 
column with 200 mM imidazole or 20mM glutathione. Concentrated proteins (~5 
ml) were applied to an equilibirated Superdex SD75 gel filtration column loaded 
with purification buffer. SDS-PAGE analysis was used to detect purity. 
 
Western Blot Analysis, Immunoprecipitation and GST Pull Down 
Cultured cells were grown in 10 cm dishes and serum starved overnight. Cells 
were either left unstimulated (basal) or stimulated with 20 ng/ml FGF9 (R&D 
Systems) for 30 min. Cells were lysed with Hepes lysis buffer (50 mM Hepes, 
pH 7.5, 1% [vol/vol] igepal-C630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 
1 mM sodium orthovanadate, 10% [vol/vol] glycerol, 50 mM NaCl, 1 mM PMSF, 
and Protease Inhibitor Cocktail Set III [EMD Millipore]) as previously described 
(2). Protein concentration was quantified by Bradford assay, and 50 µg of total 
proteins was used for every blot. For purified proteins, only 10 ng of protein was 
utilized for western blot and densitometric analysis via imageJ software (U. S. 
National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/), was performed on the blots. Protein A/G Plus-Agarose 
(Santa Cruz Biotechnology, Inc) was used for immunoprecipitation experiments.  
For GST pull down assays, cleared extract from cells expressing GST-tagged 
proteins or empty GST vector that was incubated for 2 h at room temperature 
with glutathione sepharose beads that were soaked for 30 min in PBS, washed 
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four times with PBS, and then resuspended in Tris buffer. The resultant GST-
tagged protein bound to the beads was incubated with cell lysates overnight at 
4°C before washing three times with PBS to avoid non-specific binding. This 
was followed by western blot analysis to detect protein-protein complex 
formation. Antibodies were purchased from the following sources: 
phosphotyrosine (pY99), FGFR2 (C-17), Grb2 (C-23), anti-goat secondary 
antibody, and HA-probe (Y-11) (Santa Cruz Biotechnology Inc); anti-GFP (goat) 
and anti-RFP (mouse) (Rockland Immunochemicals); β-actin, GST, and anti-
mouse and anti-rabbit secondary antibodies (Cell Signaling Technology); and 
THE™ HA-tag (mouse) and Plcγ1 (mouse) (BD Biosciences). 
Additional reagents used in experiments were purchased as follows: ATP 
competitive FGFR2 inhibitor SU 5402, scrambled shRNA, (catalog no. sc-
108080), and Grb2 shRNA (catalog no. sc-29335-v) (Santa Cruz Biotechnology, 
Inc); phalloidin (catalog. no: 8953) (Cell Signaling Technology); Metafectene 
transfection reagent (Biontex-USA); and puromycin dihydrochloride, selection 
antibiotic, (Invitrogen).  
 
Cell Fractionation 
HEK293T Ci and G2i cells were serum starved overnight. Cells were either left 
unstimulated, or stimulated with 20 ng/ml FGF9 for 30 min and then washed 
three times with PBS. Cell fractionation was performed using the Subcellular 
Protein Fractionation Kit for Cultured Cells (Thermo Scientific). The protein 
content in the cytoplasmic and membrane extracts was quantified and analyzed 
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by western blot. FGFR2 and β-actin were used to determine the purity of the 
membrane and cytoplasmic extracts, respectively. 
 
MTT Assay 
A working solution of MTT was prepared by diluting the 5 mg/ml stock solution 
(Promega) 1:10 in PBS. Cells were seeded in 12-well plates. The medium was 
aspirated and replaced with 40 µl MTT/well. Cells were then incubated for 3 h at 
37°C. The MTT dye was solubilized with 1 ml acidic isopropanol (0.04 M HCl), 
followed by two 30-min incubation periods in between which the solution was 
gently mixed. Finally, the dye solution was transferred to a 1.5 ml eppendorf 
tube and centrifuged at 13,000 rpm for 3 min. The supernatant was pipetted into 
disposable cuvettes and absorbance was measured at 570 nm with background 
wavelength subtraction at 650 nm. Results were plotted using Excel (Microsoft) 
and presented as the mean ± standard deviation of the relative fluorescence 
units (RFUs) of three independent experiments performed in triplicate.  
 
Surface Plasmon Resonance (SPR) 
SPR experiments were performed using a BIAcore T100 instrument with 
temperature maintained at 25°C in running buffer (50 mM HEPES, pH 7.5, 100 
mM NaCl, and 1 mM β-mercaptoethanol). The CSH3 of Grb2 (Grb2CSH3) was 
immobilized to Series S CM4 Sensor Chips to a final level of ~700-900 
resonance units (RU) using the manufacturer’s protocol. Synthesized FGFR2 
C-terminal peptide (23 amino acids; C23) was diluted in running buffer, and 
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binding experiments were performed using a flow rate of 30 µl/min with 180 s 
contact time and 300 s dissociation time. Data analysis was performed using 
BIAcore evaluation software with data subtraction against blank immobilized, 
paired flow-cells. 
 
Fluorescence Microscale Thermophoresis (MST) 
MST Experiments were performed using a Monolith NT.115 instrument 
(NanoTemper) with temperature maintained at 25°C. The Plcγ SH3 domain was 
labeled with primary amine coupling of NT-647 dye according to the 
manufacturer’s protocol and purified using Superdex 25 resin in a buffer 
containing 50 mM HEPES (pH 7.5), 100 mM NaCl, and 1 mM β-
mercaptoethanol. Titration series were made using a 1:1 dilution of synthesized 
FGFR2 C-terminal peptide (23 amino acids) while maintaining a constant 25 nM 
NT-647-labeled Plcγ SH3 domain. Thermophoresis was monitored at four 
separate temperature gradients. MST experiments were performed in triplicate 
while. 
 
Fluorescence Lifetime Measurement  
Fluorescenceresonance energy transfer (FRET) experiments were done to 
measure complex formation between Alexa Fluor 488-labeled C58 (emitter) and 
Alexa Fluor 555-labeled Plcγ1SH3 (acceptor). In all experiments, 250 µl of 
sample was labeled with 10 µM Alexa Fluor (Invitrogen). The sample was then 
rotated at room temperature for 1 h before quenching with 40µl Tris-Hcl (pH 8). 
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Labeled sample was separated from free dye using a gel filtration column. C58 
and Plcγ1SH3 were incubated at an equimolar concentration of 0.5 µM. 
Grb2CSH3 concentration was increased sequentially as follows: 0.1 µM, 0.5 
µM, and 0.7 µM. Experiments were performed in a spectrofluorometer 
(QuantaMaster-4-CW; Photon Technology International) at 23°C in 50 mM Tris-
HCl, 100 mM NaCl, 1 mM β-mercaptoethanol, and 5% glycerol at pH 8.5. C58 
lifetime decay was measured using a pulsed nitrogen laser with an excitation of 
488 nm, emission of 510 nm, start delay of 135 ns, and end delay of 150 ns. 
200 channels were used with an integration time of 50 µs, 3 averages, 5 shots, 
and a frequency of 8 Hz. FeliX32 analysis software (Photon Technology 
International) was used to fit the decay curves and compute the lifetime 
constants. 
 
Fluorescence Lifetime Imaging Microscopy (FLIM) Analysis 
HEK293T cells stably expressing GFP-FGFR2 were transfected with different 
RFP-tagged Plcγ1 domains or full length HA-Plcγ1 using Metafectene.  
The efficiency of transfection was confirmed using western blot analysis. Serum 
starved cells on glass coverslips were either left unstimulated or stimulated with 
20 ng/ml of FGF9. Cells were fixed with 4% (wt/vol) paraformaldehyde (pH 8.0) 
for 20 min. HA-Plcγ1-transfected cells were fixed, washed with PBS, 
permeabilized with 0.5% (vol/vol) Triton X-100, and blocked with blocking buffer 
(3% BSA, 0.5% Triton X, and 5% fetal calf serum). Cells were then washed with 
PBS and incubated overnight with Alexa Fluor 555-labeledanti-HA antibody (Y-
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11). Cells were washed with PBS and mounted onto a slide with mounting 
buffer (0.1% p-phenylenediamine/75% glycerol in PBS). Imaging was 
performed using a confocal microscope (model SP5; Leica) at 20°C as 
described previously (2). FLIM data was collected with an inverted advanced 
confocal microscope system (TCP SP5; Leica) with an internal photomultiplier 
tube detector. The samples were excited with a tunable fs titanium-sapphire 
pumped laser (Mai Tai BB; Spectra-Physics). Images were acquired with an oil-
immersion objective (NA 1.4) and a line scan speed of 400 Hz, with an image 
size of 512 × 512 pixels. Pixels used for analysis were 256 x 256. The 
fluorescence decays were fitted with a single exponential decay model using 
SPCImage software (Becker & Hickl), and the GFP fluorescence lifetimes were 
displayed in a false-color histogram. The data shown are representative of three 
slides prepared from three independent experiments.  
 
Results 
Grb2 inhibits the binding of Plcγ1 to FGFR2 
We generated Grb2 shRNA knockdown (G2i) and scrambled shRNA control 
(Ci) A431 cells (Fig 2.2a). Immunopreciptiation of Plcγ1 by FGFR2 under non-
stimulated conditions showed that the presence of Grb2 in Ci cells inhibited the 
association of Plcγ1 with the receptor (Fig 2.2b). Immunoprecipitation of Plcγ1 
by FGFR2 (Fig 2.2c) and FGFR2 by Plcγ1 (Fig 2.2d) revealed similar inhibitory 
effects in HEK293T Ci cells stably over-expressing FGFR2. A constitutive 
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Plcγ1-FGFR2 interaction was observed in G2i cells (Fig 2.2 b,c,d). Therefore, 
the Plcγ1-FGFR2 interaction occurred in the Grb2 knockdown background. 
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Fig2.2 Plcγ1 constitutively binds to FGFR2 in the absence of Grb2.a) Grb2 
knockdown in A431 G2i cells was confirmed by western blot. A431 cells 
transfected with scrambled shRNA were used as a control (Ci cells). Total Plcγ1 
and β-actin were used as loading controls.b) A431 and c) Ci (control) and G2i 
(Grb2 knockdown) HEK293T cells were serum starved overnight an either left 
Unstimulated (basal) or stimulated with FGF9. Cell lysates were obtained and 
immunoprecipitation was performed using FGFR2 antibody. The expression of 
total FGFR2 and total Plcγ1 in the immunoprecipitates was determined by 
western blot. Quantification of western blots was done using ImageJ software 
and presented in arbitrary units.d) Lysates obtained from HEK293T Ci and G2i 
cells that were unstimulated (basal) or FGF9-stimulated were used for 
immunoprecipitation with Plcγ1 antibody.Immunoprecipitates were analyzed for 
total Plcγ1 and total FGFR2 by western blot.e) In the absence of Grb2, the 
binding of Plcγ1 to FGFR2 does not induce Plcγ1 phosphorylation. HEK293T Ci 
and G2i cells were serum starved overnight and either left untreated or treated 
with 30 µM SU5402 kinase inhibitor for 2 h. Basal or FGF9-stimulated cell 
lysates were obtained and the expression of phosphorylatedPlcγ1 and 
phosphorylated FGFR2 was determined by western blot. f) Western blot result 
showing the phosphorylation state of Plcγ1 in unstimulated and FGF9-
stimulated HEK293T cells. Cell lysates from serum-starved Ci, G2i, and G2i 
cells with 0.5 µg Grb2 knocked in were obtained, and western blot was done to 
determine the expression of phosphorylated Plcγ1, total Plcγ1 (loading control), 
and Grb2 (efficiency of knockdown/knock in). g) HEK293T Ci and G2i cells 
stably transfected with GFP-tagged FGFR2 were transiently transfected with 
HA-Plcγ1. Non-transfected cells were used as controls to detect the initial 
lifetime of GFP using FLIM (top row). Constitutive Plcγ1-FGFR2 interaction 
does not occur in the presence of Grb2. However, in the absence of 
Grb2,Plcγ1-FGFR2 complex formation occurs as evidenced by the reduction in 
emission lifetime of GFP (left shift of the peak in graph; right hand column). 
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Importantly, Plcγ1 phosphorylation did not occur in HEK293T cells when Plcγ1 
was constitutively bound to FGFR2 (Fig 2.2e). FGF9-mediated FGFR2 
stimulation induced Plcγ1-FGFR2 complex formation as expected. Under these 
conditions, Grb2 binding was abrogated (1), FGFR2 was tyrosine-
phosphorylated, providing a site for the binding of Plcγ1NSH2 (Fig 2.2b,c,d), 
and Plcγ1 wasphosphorylated in Ci cells (Fig 2.2e). Knocking Grb2 back into 
G2i cells restored Plcγ1 phosphorylation in stimulated cells (Fig 2.2f).  
 
To confirm that the presence of Grb2 affects Plcγ1-FGFR2 complex formation 
in a cellular context, we performed FLIM on HEK293T Ci and G2i cells stably 
over-expressing C-terminally GFP-tagged FGFR2 (FGFR2-GFP) and 
transfected with HA-Plcγ1 (Fig 2.2g). Fluorescence lifetimes were measured 
between GFP and an Alexa Fluor 555 (AF555)-labeled anti-HA-Plcγ1 antibody. 
Under non-stimulated conditions in Ci cells, the GFP fluorescence lifetime was 
unaffected, suggesting the absence of binding between FGFR2and Plcγ1. 
However, in the absence of Grb2, the GFP fluorescence lifetime was 
significantly reduced (left shift of lifetime graph; Fig 2.2g). This reduction in 
GFP fluorescence lifetime was due to FRET between GFP (donor) and AF555 
(acceptor) as the fluorophores approach to within ~10 nm of one another, 
suggesting that FGFR2 and Plcγ1 wereclose enough to form a complex. 
Stimulation of the receptor resulted in clear protein complex formation through 
the well-characterized binding of Plcγ1 to phosphorylated receptor. 
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The SH3 domain of Plcγ1 binds to FGFR2 
To identify more precisely the FGFR2 site that interacts with Plcγ1, we 
performed pull down experiments with truncated polypeptides including the 
protein-binding domains of Plcγ1 (Fig 2.3a). Under basal conditions, a GST-
tagged polypeptide containing the NSH2, CSH2, and SH3 domains of Plcγ1 
(SH223) was able to pull down FGFR2 only in G2i cells (Fig 2.3b). Truncating 
the peptide to isolate the SH3 domain was also effective in pulling down the 
receptor (Fig 2.3b). We confirmed the interaction between the SH3 domain of 
Plcγ1 (Plcγ1SH3) and FGFR2 with additional pull down experiments using 
mutant forms of SH223 (Fig 2.3c). R586A and R694A mutants (which disable 
NSH2 and CSH2 binding to pY, respectively) and the DM did not abrogate 
binding to non-stimulated receptor in G2i cells (Fig 2.3c). This suggested that 
the SH3 domain, but not the SH2 domains, of Plcγ1 interacted with the receptor 
under non-stimulated conditions.Upon receptor stimulation, Plcγ1-FGFR2 
complex formation was observed in R694A SH223-mutated Ci cells, which was 
consistent with a previous report demonstrating binding of NSH2 to the 
activated receptor (31).   
FLIM was also utilized to assess Plcγ1SH3 binding in a cellular context. In 
HEK293T cells transfected with GFP-tagged FGFR2 and RFP-tagged 
Plcγ1SH3, binding was not observed in Ci cells under non-stimulated 
conditions. However, FGFR2-Plcγ1SH3 complex formation did occur in G2i 
cells (left shift of lifetime graph compared to isolated RFP; Fig2.3d).  
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Therefore, Plcγ1SH3 binding to FGFR2 occurred only in the absence of Grb2. 
Similar results were obtained in cells transfected with RFP-tagged SH223 of 
Plcγ1 (Fig 2.4a,b,c).  
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Fig 2.3 The SH3 domain of Plcγ1 binds to FGFR2.a) Schematic illustration of 
the sequence of Plcγ1 domains. SH223 and SH3 truncated versions shown with 
the arginine residues (R586 and R694) that were mutated in SH2 domains to 
abrogate binding topY on FGFR2.b) C-terminal GST-tagged polypeptides 
SH223-GST, SH3-GST, and GST alone (used as a control) on glutathione 
beads were incubated with cell lysates obtained from basal and FGF9-
stimulated Ci and G2i HEK293T cells. Western blot was used to determine total 
FGFR2 and GST expression.c) R586A and R694A mutations were made in the 
NSH2 and CSH2 of SH223 of Plcγ1, respectively. R586A and R694A mutants 
and DM of SH223 were used for GST pull down assays of basal and FGF9-
stimulated HEK293T whole cell lysates. d) RFP-tagged Plcγ1SH3 was 
transiently transfected in HEK293T cells stably transfected with FGFR2-GFP. Ci 
and G2i cells were used for FLIM analysis. Graph (right hand column) shows 
distribution of GFP fluorescence lifetime. Complex formation is shown by a 
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reduction of the GFP lifetime (left shift of peak). Cells transfected with empty 
RFP vector were used as a control (top row). 
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Fig 2.4 Plcγ1 binding to FGFR2 is independent of phosphorylation state.a) 
Western blot showing the efficiency of transfection of RFP-tagged SH223 and 
SH3 constructs in HEK293T control (Ci) and Grb2 knockdown (G2i) cells.Cells 
transfected with RFP empty vector were used as a control.b) HEK293T Ci and 
G2i cells stably expressing FGFR2-GFP were transfected with SH223-RFP, 
serum starved overnight, and treated with FGF9 for 30 min. Cells were washed 
and lysed before immunoprecipitation with anti-GFP antibody. Western blot 
analysis was done to determine the expression of GFP (as a control) and RFP 
to detect the association of FGFR2 with the Plcγ1 SH223 domain.c) Cells 
transfected with SH223-RFP or RFP alone were used to detect binding to 
FGFR2-GFP by FLIM. Reduced fluorescence lifetime (left shift of peaks in right 
hand column) indicates complex formation. 
c 
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The C-terminal SH3 domain of Grb2 (Grb2CSH3) binds to a peptide 
corresponding to residues 807-821 of the very C-terminus of FGFR2 (2,3). To 
determine whether Plcγ1SH3 binds to a similar region on FGFR2, we initially 
used a C-terminally GST-tagged 58 residue peptide representing the very C-
terminal sequence of FGFR2 (C58; residues 764-821). In a GST pull down 
experiment, Plcγ1 was clearly associated with C58 in non-stimulated G2i 
HEK293T cells (Fig 2.5a). In an in vitro experiment, C58 was able to pull down 
purified Plcγ1; however, this interaction was reduced in the presence of Grb2 
(Fig 2.5b).  
The Grb2CSH3-FGFR2 interface incorporates a cognate sequence including 
proline residues 810 and 813 on the receptor (2). We confirmed that Plcγ1 
binds to the same location as Grb2 in pull down assays of HEK293T cell lysates 
with C58, in which the binding site was disrupted through mutation of the C-
terminal proline residues to alanine (P810A, and P813A; Fig 2.5c). P810A and 
P813A mutations, which are in the defined Grb2CSH3 binding site, induced 
negligible complex formation in the basal state even in G2i cells. However, in 
cells with a proline to alanine mutation (P804A), which is just outside the 
structurally determined binding site for Grb2, Plcγ1 was able to bind to C58 in 
G2i cells. 
To demonstrate that the binding of Plcγ1 is independent of FGFR2 
phosphorylation in the non-stimulated state, Y769 on C58-GST was mutated to 
phenylalanine (Y769F). Complex formation between C58 and Plcγ1 was 
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observed in the absence of pY769 in G2i cells, which indicated that the Plcγ1 
and FGFR2 interaction is mediated by Plcγ1SH3 (Fig 2.5d). Conversely, the 
ability of C58 to pull down Plcγ1 from Ci cell lysates was limited. 
We confirmed the binding between Plcγ1SH3 and the C-terminal (residues 799-
821; C23) of FGFR2 in vitro using MST. The equilibrium dissociation constant 
(Kd) of this interaction was approximately 40 µM (Fig 2.5e). This is similar to the 
binding affinity of the second FGFR2 molecule to the Grb2 dimer bound to 
FGFR2 in the formation of the FGFR2-Grb2 heterotetramer (Kd ~ 25 µM) (2). 
Therefore, it is possible that approximately equimolar concentrations of 
Plcγ1SH3 and Grb2 would compete equally for binding to FGFR2 in cells (see 
schematic Fig. 2.5f). 
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Fig 2.5 Plcγ1 binds to the C-terminus of FGFR2.a) Plcγ1 binds C58 more 
effectively in the absence of Grb2. Pull down assays ofcell lysates from basal 
and FGF9-stimulated HEK293T Ci and G2i cells with C58 were performed to 
determine whether Plcγ1 binds to the C-terminus of FGFR2.Western blot 
analysis was done to determine total Plcγ1 and GST expression in the 
immunoprecipitates.b) C58 on glutathione beads was incubated with purified 
Plcγ1 alone or in combination with Grb2 (equimolar concentration of 10 ng) in a 
GSTpull down assay. The expression of Plcγ1, GST, and Grb2 was determined 
by western blot and quantitated by densitometric analysis. The histogram 
presents the ratio of Plcγ1 to GST following normalization to control cells of 3 
independent experiments. Error bars represent standard deviation of the mean 
(right panel).c) P804A, P810A, and P813A-mutatedC58 were used in a GST 
pull down assay using HEK293T cell lysates. Western blot was done to 
determine the expression of total Plcγ1 and GST.d) C58 with a point mutation 
Y769F (to which the SH2 domain(s) of Plcγ1 are known to bind) was used in a 
GST pull down assay of cell lysates from HEK293T cells,followed by western 
blot analysis. The blot was probed for total Plcγ1 and GST. e) MST was used to 
measure the binding of C23 to Plcγ1SH3. C23 was titrated with 25 nM NT-647-
labeled Plcγ1SH3 domain. Binding curve fit to a Kd = 39 µM. f) Schematic 
showing the concentration-dependent equilibrium between Grb2 and Plcγ1 for 
FGFR2 binding. Top panel: Formation of Grb2-FGFR2 heterotetramer. (1) 
Binding of first FGFR2 molecule to Grb2 dimer; Kd = 0.1 µM. (2) Binding of 
second FGFR2 molecule to Grb2 dimer; Kd ~ 25 µM. Bottom panel: Competition 
between Grb2 and Plcγ1 (only the SH domains are highlighted). (3) Increasing 
concentrations of Plcγ1 compete to disrupt the Grb2-FGFR2 heterotetramer (Kd 
~ 40 µM). (4) Under high Plcγ1 and/or low Grb2 concentrations, Plcγ1 binding 
to FGFR2 will dominate. SH2 – yellow; SH3 domain – red; FGFR2 – blue; Plcγ1 
– green. 
 
 
Plcγ1 and Grb2 compete for binding to FGFR2 
The binding of both Grb2 and Plcγ1 via their respective SH3 domains to an 
identical region of FGFR2 with similar affinities indicatesthat constitutive Plcγ1 
activation relies on a concentration-dependent competition for FGFR2 binding. 
To confirm this, an in vitro competition assay using fluorescence spectrometry 
was performed to assess whether increasing concentrations of Grb2 could 
effectively displace Plcγ1 from FGFR2. C58 was labeled with Alexa Fluor 488 
(AF488), and Plcγ1SH3 was labeled with AF555. The fluorescence lifetime of 
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AF488-tagged C58 (green arrow; Fig 2.6a) will decrease in the proximity of 
AF555 through FRET. Mixing of 0.5 µM of both C58 and PlcγSH3 reduced the 
fluorescence lifetime of AF488 (red arrow) due to PlcγSH3 and C58 complex 
formation. Subsequent addition of increasing concentrations (0.1-0.7 µM; 
maroon arrows) of Grb2CSH3 increased AF488 emission lifetimes as the 
unlabeled Grb2CSH3 replaced PlcγSH3 on C58.  
Localization to the plasma membrane is fundamental to Plcγ1 phospholipase 
lipase function. In the absence of Grb2, a significant concentration of Plcγ1 
localizes to the membrane. This was not observed in Ci cells (Fig 2.6b). These 
data are consistent with increased concentrations of Plcγ1 being recruited to 
the membrane through binding to FGFR2 under non-stimulatory conditions. 
In summary, these results show that both proteins are competing for the same 
binding site on FGFR2 in a concentration dependent manner. Thus, Plcγ1 will 
replace Grb2 on the receptor only in G2i cells under basal non stimulated 
conditions.  
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Fig 2.6 Plcγ1 and Grb2 compete for binding to FGFR2.a) Fluorescence 
spectroscopy measurement of AF555 and AF488-labeled Plcγ1SH3 binding to 
C58 in the presence of Grb2CSH3.The green arrow indicates the lifetime 
measurement (ns) of C58 (0.5 µM). The red arrow indicates the addition of 
Plcγ1SH3 (0.5 µM). The maroon arrows indicate the sequential addition of 0.1, 
0.5, and 0.7 µM Grb2CSH3 to the C58 and Plcγ1SH3 mixture. b) Expression of 
Plcγ1 in the cellular fractions of HEK293T lysates. Total FGFR2 and β-actin 
were used to determine the purity of the membrane (Mem) and cytoplasmic 
(Cyto) fractions, respectively. 
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Chapter Three: Grb2 and Plcγ1 competition 
controls lipase mediated cell migration and 
invasion 
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Background 
When it comes to the activation mechanism of Plcγ1, some features remain 
speculative. For example, tyrosine phosphorylation may not always be essential 
or adequate for full activation of Plcγ1 (33). However, phosphorylation and X/Y 
linker region-mediated intramolecular interactions are required to induce 
membrane localization and phospholipase activity (34). Thus, the previously 
described SH3-mediated binding of Plcγ1 to FGFR2 might be critical in placing 
the lipase in close proximity to its substrate, leading to phosphorylation-
independent Plcγ1 activation. 
Hydrolysis of the Plcγ1 substrate PIP2 is known to be required for the 
development of cellular protrusions, filopodia, and lamellipodia and directional 
cell migration (35,36). Plcγ1 activity has been implicated in differentiation, cell 
proliferation, chemotaxis, actin remodeling, and cell migration (37-40). Plcγ1 
functions are associated with phosphoinositide metabolism, which directly 
impacts the actin cytoskeleton (41,42).  
Here, we show that SH3-mediated binding of Plcγ1 to FGFR2 under conditions 
where the law of mass action favors Plcγ1 over Grb2 (i.e., higher intracellular 
concentration of Plcγ1 vs. Grb2) increases Plcγ1 activity and PIP2 hydrolysis, 
thereby inducing cellular invasion and metastasis. 
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Methods 
Cells 
Human embryonic kidney 293T (HEK293T), and LoVo colon cancer cells were 
maintained in Dulbecco’s modified Eagle’s high glucose medium (DMEM), 
whereas ROS17/2.8 osteosarcoma cells were grown in phenol red-free DMEM. 
DMEM was supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1% 
antibiotic/antimycotic (Lonza) in a humidified incubator at 37°C with 10% CO2. 
Grb2 (G2i), and Plcγ1 (Pγi) knockdown cells were generated by infecting cells 
Grb2 shRNA and Plcγ1 shRNA lentiviral particles, respectively, followed by 
selection with 7 µg/ml puromycin. Controls cells (Ci) were infected with 
scrambled shRNA lentiviral particles. Knockdown of Grb2 and Plcγ1 in surviving 
cells was confirmed by western blot. Cells were serum starved overnight prior to 
stimulation with FGF9 for 30 min. 
 
Western Blot Analysis, and inhibitors  
Western blot analysis method is the same as that of the previos chapter. 
Antibodies utilized are also mentioned in the “Methods” section of the previous 
chapter. Additional reagents used in this part were purchased as follows: Plc 
inhibitor U73122 (Sigma Aldrich); and Plcγ1 shRNA (catalog no. sc-29452-v) 
(Santa Cruz Biotechnology, Inc); phalloidin (catalog. no: 8953) (Cell Signaling 
Technology). 
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In vitro Plcγ1 Reconstitution Assay to Measure [3H] PI(4,5)P2 Hydrolysis. 
Synthetic 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-
glycero-3-phospho-L-serine, and 1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-
inositol-4',5'-bisphosphate) (100 µg of each) (Avanti Polar Lipids) were 
combined in chloroform:methanol (2:1) in a molar ratio of 1:1:1 with 0.6 µCi of 
[2-3H(N)] PtdIns (4,5)P2 (Perkin Elmer Life Science). Mixed phospholipid 
vesicles were created by drying the mixture under vacuum using a Savant 
Speed Vac Concentrator, resuspending the dried lipid mixture, and dispersing 
on ice by sonication using a probe sonicator at amplitude 15% for 1 min 
(Branson Digital Sonifier) in 1 ml of 20 mM Hepes pH 7.4, 20 mM NaCl, 4 mM 
EGTA, 8 mM MgCl2, 220 mM KCl, and 0.15 mM CaCl2. Sodium cholate was 
added to achieve a final concentration of 0.1% and dissolved by vortexing. To 
perform the assay, a radiolabeled substrate was provided as mixed 
phospholipid vesicles (100 µl), which were complemented with cholate (as 
described above) and combined with an equal volume of cell lysate. The 
purified proteins were utilized in experiments to determine enzyme activity and 
potential regulation by kinase dead FGFR2, Grb2, and Plcγ1CSH3 (100 µl). 
Full-length Plcγ1 was purchased from EMD Millipore. Cell lysates were derived 
from HEK293T cells. Assays were performed for 2 h at 37°C and terminated by 
the addition of 0.75 ml of chloroform/methanol/HCl (20:40:1), followed by the 
addition of 0.25 ml chloroform and 0.25 ml of 0.1 M HCl. Samples were 
vigorously vortexed for 1 min and then centrifuged for 1 min.  
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Aliquots (100µl) of the upper aqueous (containing the PIP2 hydrolysis product 
IP3) and bottom (containing the Plcγ1 substrate PIP2) phases were collected, 
dried on GF/F glass microfiber filter, quantitated by liquid scintillation 
spectrometry, and normalized to protein concentration. To demonstrate that 
other proteins were not involved in the phospholipid turnover in our study, 
controls consisting of buffers and purified proteins were assayed for PIP2 
turnover (Fig 3.1). 
 
Fig 3.1 Controls for phospholipase in vitro reconstitution assays. The ratio 
of [3H]IP3 to [3H]PIP2 was determined and normalized to Plcγ1 plus kinase dead 
receptor. Values shown represent the mean ± standard deviation of three 
independent experiments. 
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Assay of Plcγ1 Activity in Whole Cells 
Cellular Plcγ activity was estimated from the measurement of the steady-state 
level of PIP2 in [3H]myo-inositol uniformly radiolabelled cells because the PI3K 
pathway utilizes only a very  small fraction of the PI(4,5)P2 pool compared with 
that hydrolyzed by Plc, and the contribution of reutilization of dephosphorylated 
[3H]inositol released from PIP2 is negligible (43).  
To measure cellular amounts of phosphoinositides, HEK293T cells were pre-
labeled with myo-[2-3H(N)]inositol (1 µCi/ml)  (Perkin-Elmer) for 24 h in inositol-
free, FBS-free DMEM medium. Cells were then incubated for 30 min with 20 
ng/ml FGF9 and washed with PBS. After labeling, cells were harvested, 
washed, and subjected to lipid extraction and thin layer chromatography (TLC) 
analysis.  
 
Lipid Extraction and TLC Analysis 
Lipid extraction and TLC analysis was performed using the Bligh Dyer method 
(44) with some important modifications. The HEK293T cell pellet was 
resuspended in 0.2 ml of 0.5 M NaCl in 0.1 M HCl, and then 0.6 ml of 
chloroform:methanol (1:2) was added and vigorously vortexed for 30 min. An 
additional 0.2 ml of 0.5 M NaCl in 0.1 M HCl was added and vortexed for 10 
min. After a 5-min centrifugation in an Eppendorf Table Centrifuge, the upper 
water-methanol phase (containing IP3) was discarded, and the lower chloroform 
lipid phase (containing PIP2) was carefully transferred to a new eppendorf tube. 
The lipid extract (10 ml) was dried on a GF/F glass microfiber filter and counted 
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in a scintillation counter. Lipid extracts were immediately analyzed by TLC. To 
ensure that the same volumes were used in the TLC analysis, the 25,000 cpm 
aliquots were diluted with chloroform when necessary. Prior to silica gel TLC 
analysis, PI(4,5)P2 and PI(3,5)P2 were separated by one-dimensional TLC on 
potassium oxalate-impregnated silica gel plates using a highly polar solvent 
system containing chloroform/methanol/ammonium hydroxide/water 
(57:50:4:11, vol/vol/vol/vol) (45). High-performance Partisil LK5 silica gel-
precoated TLC plates (20 cm) with a concentration-zone (Whatman Inc. Clifton, 
NJ) were impregnated for 1 min in 1.2 % (wt/vol) potassium oxalate in 
methanol-water (2:3). After air drying for 15 min, the plates were desiccated at 
100°C for 60 min before use. Radiolabeled lipids were visualized and quantified 
using a Personal Molecular ImagerTM FX (Bio-Rad Laboratories). Stored 
images were processed and quantified using Quantity One software for 
scanning and analysis of the captured Phosphor images (Bio-Rad 
Laboratories). Phospholipid content was expressed as mol% of total 
phospholipid based on the pixel intensity of the captured signal on Phosphor 
screen generated by the radiolabeled spots on the TLC plate. Phospholipids 
were identified based on their retardation factor (Rf) using different 
phosphoinositides as standards. 
 
Intracellular Calcium 
The intracellular calcium concentration was measured with use of the Fura-2AM 
fluorescent indicator. Data was obtained as described previously (46,47). 
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Briefly, HEK293T cells were incubated with 5µM Fura-2AM (Calbiochem) at 
room temperature for 1 h in the dark and washed with MBSS solution (140mM 
NaCl, 5.4mM KCl, 0.5 mM MgCl2, 0.4 mM MgSO4, 3.3 mM NaHCO3, 2 mM 
CaCl2, 10 mM HEPES, and 5.5 mM glucose at pH 7.4). Imaging was performed 
with use of an InCyt Im Imaging workstation (Intracellular Imaging, Inc.), Nikon 
Eclipse TS 100 inverted microscope, and a 12-bit CCD camera (Pixel Fly, 
Cooke). Fura-2-loaded cells were excited alternately at 340 and 380 nm, and 
the fluorescence emission at 510 nm was measured. The F340/F380 emission 
ratio was used as an index of intracellular calcium.  
For each experiment, the responses of 20-30 cells were monitored and their 
fluorescence emission ratios averaged at the end of recording. Ratios were 
converted to an intracellular calcium concentration ([Ca2+]i) using the equation: 
[Ca2+]i = Kdβ(R-Rmin)/(Rmax-R), where Kd is the Ca2+ dissociation constant of 
Fura-2, β is the ratio of the fluorescence emission intensity of 380 nm excitation 
in Ca2+-depleting and Ca2+-saturating conditions, R is the ratio at any time, Rmin 
is the minimum ratio in Ca2+-depleting conditions (measured in the presence of 
0 mM extracellular Ca 2+, 5 µM EGTA, and 2 µM ionomycin), and Rmax is the 
maximum ratio in Ca2+-saturating conditions (measured in the presence of 10 
mM extracellular Ca2+ and 2 µM ionomycin)(51). 
 
Wound Healing Assay 
HEK293T Ci, G2i, and Pγi cells were left untreated or transiently transfected 
with the appropriate construct. Briefly, cells were seeded into a 12-well plate 
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until they reached full confluency. After overnight serum starvation, the surface 
of the cells was scratched with a pipette tip. Cells were washed three times with 
PBS and then incubated in 1% serum for 6 h with or without U73122 (for Ci and 
G2i cells). Images were taken using a confocal microscope (model SP5; Leica) 
after 0 h and 6 h. The average distance traveled by the cells between six 
arbitrarily chosen points along the wound was quantified in three independent 
experiments. The percentage of wound closure was calculated in each 
experiment and normalized to that of controls. Values are presented as the 
mean ± standard deviation.Differences in the percentage of wound closure 
were evaluated using theStudent’s t-test. 
 
Invasion Assay 
Matrigel Invasion Chambers in two 24-well plates with 8.0 µm pores were 
purchased from BD Biosciences. Briefly, cells were counted via a 
hemocytometer using trypan blue to exclude dead cells. Following rehydration 
of the chambers, 5 x 104 cells in 0.5 ml serum-free medium were seeded into 
the upper chamber. Serum-containing (1%) medium (0.75 ml) was added to the 
lower chamber. After incubation for 6 to 24 h in a humidified incubator at 37°C 
with 10% CO2, non-invasive cells were scraped off the membrane with cotton 
swabs, and invasive cells were fixed and stained using the Hema 3 Stat Pack 
(Fisher Scientific). After drying, membranes at the bottom of each chamber 
were pealed, mounted onto a slide with mounting buffer (0.1% p-
phenylenediamine/75% glycerol in PBS), and covered with a glass cover slip. 
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Images were taken using a Leica inverted microscope. The number of invasive 
cells were counted in four different microscopic fields and are presented as the 
mean ± standard deviation of triplicate samples. Differences in the number of 
invasive cells were compared using the Student’s t-test. It is important to note 
that metastatic LoVo cells exhibit slower growth and migratory properties 
compared with HEK293T cells. Also, ROS cells were larger in size and hence, 
the number of cells counted per field was lower. Therefore, relative 
comparisons of invasion were not performed between cell lines.  
 
Flow Cytometry and Imaging of Actin Polymerization 
HEK293T Ci and G2i cells were seeded in 6-well plates at equal confluency. 
Serum-starved cells were detached and treated with 1% serum to detect any 
early signaling related to changes in actin polymerization. Cells were then 
detached again with versene (Lonza), suspended in DMEM, and centrifuged for 
5 min at 1000 rpm. The supernatant was aspirated, and the pellet was 
suspended in 1 ml of cold PBS. Cells in suspension were then pipetted with 
gentle vortexing into 2.5 ml of pure ice cold-ethanol to achieve a final ethanol 
concentration of 70%. Suspended cells were incubated at -20°C overnight. 
Cells were pelleted at 1500 rpm for 5 min and incubated in 500 µl phalloidin 
solution diluted in PBS containing 0.05% Triton X-100, and 0.1 mg/ml RNase 
for 60 min at 37°C.The solution was transferred to a 5-ml round bottom 
polystyrene tube for flow cytometry. The Gallios Flow Cytometer (Beckman 
Coulter) was used. GFP-/phalloidin-, GFP+/phalloidin-, and GFP-/phalloidin+ cells 
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were used as controls, and GFP+/phalloidin+ cells were gated. The geometrical 
Y-mean value was used as a measure of actin polymerization. Values were 
normalized to control cells and presented as the mean ±standard deviation of 
triplicate samples. 
For actin imaging, detached cells in 1% serum on coverslips were fixed with 
paraformaldehyde, permeabilized, blocked as previously described, and treated 
with Hoescht for 15 min at a dilution of 1:10,000. Cells were then washed with 
PBS, incubated with phalloidin solution, mounted onto coverslips, and imaged 
using aconfocal microscope (model SP5; Leica). 
 
Data Base Analysis 
All analyses were performed in R (version 3.0.1) (http:///www.r-project.org/).  
Clinical information was downloaded, and CEL (Affymetrix U133Plus2) array 
files supplied with the paper from reference 48. justRMA was used to compute 
expression values.    
Clinical information and level2 Affymetrix (Affymetrix U133 Array Plate Set) 
gene expression data publicly available from the Cancer Genome Atlas Project 
(TCGA; http://tcga-data.nci.nih.gov/) for ovarian serous cystadenocarcinoma 
were also downloaded. Homogeneity between cohorts is important for valid 
comparisons. Therefore, tumors of low malignant potential, non-serous tumors, 
and tumors other than ovarian or peritoneum were excluded. Samples from 
patients who received chemotherapy were also excluded. 
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For each cohort (TCGA, reference 48), the relationship between 
FGFR2/Plcγ1/Grb2 expression and overall survival was evaluated.  To do this, 
patients were grouped into percentiles according to mRNA expression. The 
Log-rank test was employed to determine the association between mRNA 
expression and survival, and the Kaplan-Meyer method was used to generate 
survival curves. Cut-off points to significantly split (log-rank test p-value <0.05) 
the samples into low/high mRNA groups were recorded. The cut-off to optimally 
separate the patients in both data sets (smallest p-value in each of the cases) 
was chosen. In each cohort, we added second and third expression levels to 
gain further insight into the association between FGFR2/Plcγ1/Grb2 expression 
and overall survival.Therefore,in the second expression level, the cohort was 
divided into four groups according to low/high gene1 expression and low/high 
gene2 expression.To do this,the optimal cut-off levels for gene1 and gene2 
were determined as described above.Survival rates between the low 
FGFR2/high Plcγ1 and high FGFR2/low Plcγ1 groups were compared with the 
low FGRF2/low Plcγ1 and high FGRF2/high Plcγ1. Similar comparisons were 
made for the FGFR2/Grb2 groups.  Larger differences in median survival times 
were observed when the expression levels of two genes was included in the 
analysis instead of single gene expression. Furthermore, significantly larger 
differences in median survival times were observed with the addition of the third 
expression level compared with the second expression level.  
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Results 
Competition between Plcγ1 and Grb2 dictates signaling response 
To demonstrate the competition between Grb2 and Plcγ1 in non-stimulated 
conditions, HEK293T Ci and G2i cells were transfected with 0.5 µg of HA-Plcγ1 
or left untransfected (Fig 3.2a) and serum starved overnight. Cell lysates were 
obtained and incubated with radioactive substrate either for 2 h (Fig 3.2b) or 
overnight (Fig 3.2c). In Ci cells, an increase in Plcγ1 lipase activity was 
observed with increased Plcγ1 expression, suggesting that Plcγ1 can displace 
Grb2 from FGFR2 binding (Fig 3.2b). Increased expression of Plcγ1 in the 
absence of Grb2 also increased phosphoinositide turnover, presumably due to 
the additional availability of FGFR2 for complex formation with Plcγ1.  
In a similar experiment, the competitive binding between Plcγ1 and Grb2 was 
demonstrated under non-stimulated conditions in Grb2-overexpressing cells 
(Fig 3.2c). As expected from previous experiments, G2i cells showed elevated 
IP3 production compared with Ci cells (Fig 3.2d). Increasing the expression of 
Grb2 (0.5 µg and 1 µg plasmid) in G2i cells resulted in Grb2-mediated 
displacement of Plcγ1 bound to FGFR2 with a concomitant reduction in IP3: 
PIP2 ratio. These findings highlight that the concentration-dependent 
competition between Grb2 and Plcγ1 for FGFR2 binding controls basal cellular 
phospholipase activity. 
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Fig 3.2 Competition between Plcγ1 and Grb2 dictates signaling response. 
a) HEK293T Ci and G2i cells were either left untransfected or transfected with 
0.5 µg of Plcγ1 and serum starved overnight. Cell lysates were obtained, 
andthe expression of total Plcγ1 and β-actin (loading control) was determined 
by western blot. b) Phospholipase assay was done to determine the ratio of 
[3H]IP3 to [3H]Ptldlns(4,5)P2 (PIP2) in untransfected and HA-Plcγ1-transfected 
HEK293T Ci and G2i cells. Cells were incubated with [3H]Ptldlns(4,5)P2 
substrate for 2 h. Values shown represent the mean ± standard deviation of 
three independent experiments.c) Phospholipase assay was performed on 
untransfected and HA-Plcγ1-transfected serum-starved HEK293T Ci and G2i 
cells that were incubated with [3H]Ptldlns(4,5)P2substrate for 24 h.The ratio of 
[3H]IP3 to [3H]Ptldlns(4,5)P2 was calculated after scintillation counting. Values 
shown represent the mean ± standard deviation of three independent 
experiments. d) Serum-starved HEK293T Ci cells were left untransfected 
andG2i cells were either untransfected or transfected with increasing amounts 
of myc-tagged Grb2 (0.5 µg and 1 µg). Cell lysates were obtained and western 
blot analysis was performed to determine the expression of Grb2 and the 
loading controls total Plcγ1 and β-actin.e) Grb2 downregulates Plcγ1 activity. 
Cellular phospholipase assay was used to determine the activity of Plcγ1 in 
untransfected and myc-Grb2-transfected G2i HEK293T cells (0.5 µg and 1 µg). 
Five independent measurements were made for each experiment. The data 
was normalized to control cells, and normalized data were used to calculate the 
standard deviation. 
 
                             e 
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Plcγ1 is constitutively active upon FGFR2 binding 
To establish whether Plcγ1 recruitment to FGFR2 is sufficient to promote 
enzyme activity, the steady-state level of PIP2 substrate was determined in 
HEK293T Ci and G2i cells. To do this, cells were incubated overnight under 
serum starvation conditions with radioactive myo-[2-3H] inositol. Lipids were 
extracted, separated, and identified by TLC. Quantification of TLC bands 
showed that PIP2 concentration was ~50% lower in G2i cells compared with Ci 
cells (Fig 3.3a). Therefore, a higher concentration of PIP2 was turned over in 
the absence of Grb2 under non-stimulated conditions. We confirmed this 
observation by measuring phosphoinositide turnover in total cell lysates of 
equal protein concentration prepared from Ci and G2i cells incubated with 
radiolabeled PIP2 for 2 h. After phase separation, the IP3 product and remaining 
PIP2 substrate were quantified using scintillation counting, and the IP3 to PIP2 
ratio was calculated (Table 3.1). In the G2i background, a dramatic increase in 
phospholipase activity as measured by PIP2 turnover was observed in the non-
stimulated state (Fig 3.3b).  
Further confirmation of the constitutive upregulation of Plcγ1 activity in the 
absence of Grb2 was provided by the dramatic increases in basal [Ca2+]i and 
F340/F380 emission ratio in G2i cells compared with Ci cells (Fig 3.3c). Basal 
[Ca2+]i was increased approximately five-fold and 2.5-fold in G2i cells compared 
with Ci cells, respectively ([Ca2+]i,~55 nM vs. ~250 nM; F340/F380 ratio, 0.2 vs. 
0.5; Fig 3.3d). Addition of ionomycin (a Ca2+ ionophore) resulted in the 
expected increase in calcium concentration, which confirmed that the cells were 
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functional (see arrows Fig 3.3c,e). The low [Ca2+]I in parental HEK293T cells, 
which have negligible FGFR2 expression, demonstrated that the increasein 
Plcγ1 activity was due to FGFR2 recruitment and not to non-specific binding to 
the lipid membrane (Fig 3.3e,f,g). Furthermore, overexpression of HA-Plcγ1 in 
parental cells failed to increase [Ca2+]i to the levels observed in the presence of 
FGFR2 in G2i cells (Fig3.3e,f).   
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Fig 3.3 Plcγ1 is constitutively active in the absence of Grb2.a) HEK293T Ci 
and G2i cells were labeled with radioactive myo-[2-3H]inositol overnight and 
then serum starved. Cells were left untreated or stimulated with FGF9. Lipids 
were extracted, separated by TLC, and PIP2 and PIP3 were identified. PIP2 
bands are shown. b) HEK293T Ci and G2i cells were loaded with Fura 2-AM. 
[Ca2+]i, and F340/F380 emission ratio were plotted after calibrating the 
measurements to detect their specificity and sensitivity for Fura 2-AM. 
Ionomycin was added to detect effective transfer of Ca2+ across cell 
membranes. Arrows indicate the timepoint of ionomycin addition. c) [Ca2+]i and 
F340/F380 emission ratio were determined from 0 to 2 min in Ci and G2i cells. 
Values shown represent the mean ± standard deviation of three independent 
experiments.*Student’s t-test (p value ≤ 0.05). d) Parental HEK293T cells, 
which have low endogenous FGFR2 expression, were left untreated or 
transfected with 0.5 µg of Plcγ1. Cells were loaded with Fura 2-AM, and [Ca2+]i 
and F340/F380 ratio were plotted. Arrows indicate the timepoint of ionomycin 
addition. e) [Ca2+]i and F340/F380 ratio from 0 to 2 minutes were determined in 
parental cells. Values shown represent the mean ± standard deviation of three 
independent experiments. f) Western blot was performed on cell lysates from Ci 
cells and parental HEK293T cells to show the negligible level of FGFR2 
expression in parental cells (upper panel). g) Western blot showing the 
efficiency of HA-Plcγ1 transfection in serum-starved parental cells (lower 
panel). The expression of total FGFR2, total Plcγ1, and β-actin in f) and g) was 
determined in non-transfected and HA-Plcγ1-transfected parental cells. 
f 
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Table 3.1 Examples of the upper phase and lower phase counts (prior to 
averaging) from the 2-h lipase assay in a) cell lysates and b) purified 
proteins. The calculated ratio of [3H]IP3 to [3H]Ptldlns(4,5)P2and [3H]IP3 release 
in pmol are shown. [3H]IP3 release was calculated based on the initial cpm value 
of substrate used and converted to pmol:  (cpm of [3H] IP3 x 7.5)/4415. 
 
 
Grb2 knockdown results in Plcγ1 recruitment to FGFR2 and positively regulates 
Plcγ1 activity in the non-stimulated state. We showed that these events are 
mutually dependent by adopting an in vitro reconstitution assay to assess 
whether the binding of isolated Plcγ1 to FGFR2 can activate phospholipase 
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PIP2 turnover in the presence and absence of Grb2. To ensure that the receptor 
and Plcγ1 remained unphosphorylated, a kinase dead FGFR2 (FGFR2KD) was 
generated by K517I point mutation. Unphosphorylated Plcγ1 and FGFR2KD (10 
µM) were incubated for 2 h with radioactive PIP2, and the ratio of IP3 to PIP2 
was calculated (Fig 3.4a). In the presence of FGFR2KD, Plcγ1 exhibited a high 
level of in vitro phospholipase activity. Addition of either Grb2 or Grb2CSH3 to 
the Plcγ1 and FGFR2KD mixture significantly reduced phospholipase activity 
(Fig 3.4a).This strongly suggested that the binding of Plcγ1 to 
unphosphorylated FGFR2 is sufficient to upregulate phospholipase activity and 
that Grb2 inhibits this interaction.  
To show that the increase in phospholipase activity is independent of Plcγ1 
phosphorylation, lipid turnover was measured in two Plcγ1 mutants: Plcγ1TM, 
all tyrosines in the X/Y linker region (Y771F, Y775F, Y783F) and C-terminal 
(Y977F, Y1253F) were mutated to phenylalanine (Fig 3.4b) and Plcγ1DM, both 
SH2 domains were disabled with R586A and R694A mutations (Fig 3.4b). 
Overexpression of both Plcγ1TM and Plcγ1DM increased phospholipase 
activity (Fig 3.4c). 
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Fig 3.4 Plcγ1 SH3-mediated phospholipase activity is concentration 
dependent and phosphorylation independent. a) In vitro reconstitution assay 
showing the inhibitory effect of full-length Grb2 andGrb2CSH2 on Plcγ1 activity. 
The ratio of [3H]IP3 to [3H]PIP2 was computed, and values shown represent the 
mean ± standard deviation of three independent experiments. *Student’s t-test 
(p value ≤ 0.05). Insert: Western blot demonstrating that the Plcγ1 used in these 
experiments was unphosphorylated (left lane). Incubation of Plcγ1 with the 
cytoplasmic portion of FGFR2, ATP, and MgCl2 induced Plcγ1 phosphorylation - 
positive control (right lane). The blot was probed with anti-pY (showing 
phosphorylated protein; lower panel) and anti-Plcγ1.b) Plcγ1 is active in the 
absence of phosphorylation and intramolecular SH2 domain interactions. Five 
point mutations where made in full-length HA-Plcγ1 (Y771F, Y775F, Y783F, 
Y977F, and Y1253F; TM; http://www.phosphosite.org). Two point mutations 
were made in the CSH2 and NSH2 of full-length HA-Plcγ1 (R586A and R694A; 
DM). Serum-starved HEK 293T cells were transiently transfected with DM, TM, 
or left untransfected (NT). Western blot analysis was done to detect the 
efficiency of transfection. The membrane was probed with the following 
antibodies: anti-HA, anti-total Plcγ1, and anti-β-actin (loading control). c) 
Cellular lipase assay was performed on cell lysates obtained from 
untransfected, DM-transfected, and TM-transfected serum-starved HEK293T 
cells. [3H]IP3 to [3H]Ptldlns(4,5)P2  ratios were normalized tocontrol cells. Error 
bars represent the standard deviation. Both TM and DM are able to turnover 
lipid. Elevated concentrations of the Plcγ1 mutants are capable of outcompeting 
endogenous Grb2 for binding to FGFR2. In G2i cells, the difference in lipid 
turnover was less dramatic, presumably because the competition for FGFR2 
binding is reduced in the absence of Grb2.  
 
 
Competition between Plcγ1 and Grb2 dictates cell migration and invasion 
Previous reports have demonstrated that upregulation of Plcγ1 activity 
increases cellular motility and metastasis (17). Grb2 and Plcγ1 compete for 
binding to FGFR2; therefore, in situations where the respective concentrations 
of the proteins favor Plcγ1 binding, we would expect an increase in cell motility 
and invasion. We used a wound healing assay to investigate the physiological 
outcome of the competition between Plcγ1 and Grb2 for FGFR binding. Motility 
was increased in G2i basal cells compared with Ci basal cells (Fig 3.5a,b). A 
dramatic increase in cell motility in the absence of Grb2 was observed by 
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monitoring the wound healing assay over a 24-h period using time lapse 
microscopy (videos are not included in this report). Our findings are consistent 
with previous reports demonstrating that upregulation of Plcγ1 phospholipase 
activity in the absence of Grb2 increases cell motility by increasing cellular 
calcium concentrations (14,49,50). To demonstrate that the competition 
between Plcγ1 and Grb2 dictates cell migration response, we overexpressed 
Plcγ1DM in Ci cells. Plcγ1DM is incapable of binding to pY on FGFR2 and, thus 
any effect of Plcγ1 activity will be due to SH3-mediated recruitment. Cell motility 
and [Ca2+]i were greater in Plcγ1DM Ci cells than in untransfected Ci cells (Fig 
3.5c,d,e,f). MTT assay confirmed that cell viability was unaffected by 
transfection of DM (Fig 3.5 g). Ci and G2i cells treated with the phospholipase 
inhibitor U73122 and HEK293T Pyi cells stably overexpressing FGFR2 induced 
negligible wound healing capability (Fig 3.5 h,i), confirming that the observed 
wound healing was due to Plcγ1. Also, MTT assay demonstrated that the 
observed wound healing was not due to reduced cell viability (Fig 3.5 j). Plcγ1 
knockdown in Pyi cells was confirmed by western blot (Fig 3.5 k). 
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Fig 3.5 Plcγ1 activity increases cell motility in the absence of Grb2. a) 
Wound healing assays were performed in triplicate on HEK293T Ci and G2i 
cells treated with 1% serum for 6h. Images were taken at the beginning of the 
experiment (0 h) and at 6 h. b) Distance traveled by HEK293T Ci and G2i cells 
was quantified in three independent experiments. The percentage of wound 
closure was calculated, averaged, and normalized against control cells. Values 
shown represent the mean ± standard deviation. *Student’s t-test (p value ≤ 
0.01).c) Untransfected and DM-transfected Ci cells were used in a scratch 
wound healing assay. Cells were treated with 1% serum. Images were taken at 
0 h and 6 h. d) The percentage of wound closure was measured, averaged, and 
normalized against control cells. Values shown represent the mean ± standard 
deviation of three independent experiments. e) DM-transfected HEK293T Ci 
cells were loaded with Fura 2-AM in Hanks’ buffer, and basal calcium release 
was determined by measuring [Ca2+]i and F340/380 emission ratios. Ionomycin 
was added to detect effective transfer of Ca2+ across cell membranes. Arrows 
indicate the time ofionomycin addition. f) Calcium release was compared 
between untransfected and DM-transfectedHEK293T Ci cells. Calcium release 
was determined by measuring [Ca2+]i and F340/380 emission ratiofrom 0 to 2 
min. Values shown represent the mean ± standard deviation of  three 
independent experiments. g) MTT assay was performed on untransfected and 
DM-transfected Ci cells. Values shown represent the mean ± standard deviation 
ofthreeindependent experiments. h) Wound healing assay was performed on 
HEK293T Ci and G2i cells treated with 1% serum containing 9 µM U73122 and 
Plcγ1 knockdown (Pγi) cells. Images were taken at the beginning of the 
experiment and at 6 hours.i) Distance traveled by untreated and U73122-
treated cells was quantified, and the normalized percentage of wound closure 
was calculated. Values shown represent the mean ±standard deviation of three 
independent experiments.j) MTT assays were performed to demonstrate the 
lack of effect of Grb2 and Plcγ1 knockdown, scrambled shRNA transfection, 
 
j 
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and U73122 treatment on cell viability.k) Western blot showing the efficiency of 
Grb2 and Plcγ1 knockdown in G2i and Pyi HEK293T cells, respectively. 
 
 
 
We also determined whether the competition between Plcγ1 and Grb2 affects 
cell invasion properties (Fig 3.6a,b). At 6 and 24 h, G2i cells had an increased 
invasive capacity compared with Ci cells. This can be specifically attributed to 
Grb2 knockdown because invasion decreased with increasing 
Grb2concentrations in HEK293T cells (Fig 3.6c,d). Similar results were 
obtained in LoVo metastatic human colon adenocarcinoma cells, which express 
low levels of Grb2 and high levels of FGFR2 (top panel, Fig 3.6g) (51). After 24 
h in the presence of increasing concentrations of Grb2, the number of invaded 
LoVo cells was reduced (Fig 3.6c,d,e).  
The inhibitory effect of Grb2 on invasion was further confirmed in Ci and G2i 
cells generated from the Rat osteosarcoma ROS17/2.8cell line, which 
expresses endogenous levels of FGFR2 (Fig 3.6h). Inhibition of Plcγ1 by 
U73122 treatment or knockdown decreased the invasive ability of HEK293T, 
LoVo, and ROS cells (Fig 3.6f,i). Downregulation of Plcγ1 expression in LoVo 
and ROS Pyi cells was confirmed by western blot (Fig3.6g[bottom panel],h) 
The inhibitory effect of Plcγ1 downregulation was not due to decreased cell 
viability as confirmed by MTT assay (Fig 3.6j).  
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Fig 3.6 Plcγ1 activity increases invasive behavior in the absence of 
Grb2.a) Matrigel invasion assays were used to determine whether the 
competition between Plcγ1 and Grb2 dictates invasion. HEK293T Ci and G2i 
cells were placed in the upper chamber in serum starvation medium, and 1% 
serum was placed in the lower chamber. Images were taken after 6 h and 24 h. 
G2i cells are more invasive than Ci cells at both timepoints. b) The number of 
invasive cells was counted in four microscopic fields for each sample. Values 
shown represent the mean ± standard deviation of triplicate samples.c) 
Invasion assay was performed on HEK293T G2iand LoVo cells transfected with 
increasing concentrations of Grb2 (0.5 µg and 1 µg). Images were taken after 
24h. G2i (left) and LoVo (right) cells transfected with 0.5 and 1 µg Grb2. d) The 
number of invasive cells was counted in 4 microscopic fields. Values shown 
represent the mean ± standard deviation of triplicate samples.e) LoVo cells 
were left untransfected or transfected with myc-tagged Grb2 (0.5 µg, and 1 µg). 
Cells were serum starved overnight. Cell lysates were obtained, and the 
efficiency of Grb2 transfection was determined by western blot analysis. Total 
Plcγ1 and tubulin were used as loading controls. f) (Top panel) Invasion assays 
were performed on Ci, G2i, and Pγi HEK293T;Ci, G2i, and Pγi ROS cells; and 
Ci and Pγi LoVo cells. LoVo cells have a relatively low level of endogenous 
Grb2 expression. (Middle panel) Invasion assays were performed on untreated 
U73122-treated HEK293T and ROS Ci and G2i cells. U73122 wasadded tothe 
upper and lower chambers ata final concentration of 9 µM. (Bottom 
panel)Invasion assays were performed on LoVo cells (untransfected with 
shRNA)that were left untreated or treated with U73122. In all cases, cells were 
incubated for 24 h, fixed, stained, mounted onto microscopic slides, and imaged 
at 20X magnification.g) (Top panel)Western blot was performed to determine 
total Plcγ1 and Grb2 expression incell lysates obtained from serum-starved 
HEK293T Ci and G2i cells and LoVo cells. β-actin was used as loading 
control.(Middle panel)Western blot results showing the efficiency of Plcγ1 
knockdown in LoVo Pyi cells. The membrane was probed for total Plcγ1, Grb2, 
and β-actin. h) Western blot showing the efficiency of Grb2 and Plcγ1 
knockdown in ROS G2i and Pyi cells, respectively. Ci cells were used as 
controls. The membrane was probed for total Plcγ1, Grb2, and β-actin.i) The 
number of invasive cells was counted in four microscopic fields and presented 
as the mean ± standard deviation of triplicate samples.j) MTT assays were 
performed to confirm that the inhibitory effects of Grb2 and Plcγ1 
downregulation were not due to adverse effects oncell viability. Values are 
expressed as relative fluorescent units (RFUs) and presented as the mean ± 
standard deviation of three independent measurements. 
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To test whether the Plcγ1-dependent invasive potential requires FGFR2, 
parental HEK293T cells, in which FGFR2 expression is negligible, were 
transfected with scrambled shRNA, Grb2 shRNA, and Plcγ1 shRNA to generate 
PCi, PG2i, and PPYi cell lines, respectively (Fig 3.7a). After 24 h, PPYi cells 
exhibited limited invasive ability (Fig 3.7b,c) compared with PG2i cells. Cell 
viability was confirmed by MTT assay (Fig 3.7d). 
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Fig 3.7 Invasive behavior in cells is FGFR2 dependent. a) HEK293T 
parental cells, which express low levels of FGFR2 were used to generate stable 
Grb2 (PG2i) and Plcγ1 (PPγi) knockdowns. Cells transfected with scrambled 
shRNA (PCi) were used as a control. Western blot analysis was done to 
determine the efficiency of the Grb2 and Plcγ1knockdown. β-actin was used as 
a loading control. b) PCi, PG2i, and PPγi cells were used in a 24-h invasion 
assay. c) The number of invasive PCi, PG2i, and PPγi cells was counted in four 
microscopic fields and presented as the mean ± standard deviation of three 
independent experiments performed in triplicate. d) Cell viability of PCi, PG2i, 
and PPγi cells was determined by MTT assay. Data shown represent the mean 
±standard deviation of three independent experiments.  
 
 
Next, we evaluated the effect of Plcγ1 on morphological changes associated 
with invasive behavior, including actin polymerization. Changes in the actin 
cytoskeleton precede cell migration and invasion. Therefore, phalloidin staining 
was used to detect changes in actin polymerization in HA-Plcγ1-transfected Ci 
and G2i cells. Under basal conditions, Plcγ1 was localized on migratory 
structures in G2i cells compared withCi cells (Fig 3.8a). Furthermore, G2i cells 
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were larger and had more spread cell morphology and extensions compared 
with Ci cells (Fig 3.8b).  
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Fig 3.8 Plcγ1 localizes on migratory structures in G2i cells. a) HEK293T Ci 
and G2i cells stably expressing FGFR2-GFP were transiently transfected with 
HA-Plcγ1. Serum-starved cells were treated with Alexa Fluor 555-labeled HA-
antibody.Microscopy was used to detect Plcγ1 and FGFR2 colocalization 
(yellow).High magnification view of Plcγ1 and FGFR2 colocalization on 
migratory structures (lower far right panel). b) HEK293T Ci and G2i cells were 
detached and treated with 1% serum for 2 h. Cells were stained with phalloidin 
to detect actin polymerization and counterstained with Hoechst (nuclear stain). 
Actin polymerization was induced in G2i, but not Ci, cells as evidenced by 
phalloidin staining intensity and morphological changes. 
 
 
Flow cytometric analysis further confirmed the induction of actin polymerization 
by Plcγ1 activation in the absence of Grb2. Cells with both GFP and phalloidin 
were counted in Ci and G2i (knockdown cells) samples (Fig 3.9a,b). Following 
quantification and normalization to Ci cells, a ~36% increase in actin 
polymerization was observed in G2i cells (Fig 3.9c). 
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Fig 3.9 Actin polymerization is higher in G2i cells compared withCi cells. 
a), b) HEK293T Ci and G2i cells were treated with 1% serum for 2 h,counted, 
fixed, and stained with phalloidin. Flow cytometricanalysis of phalloidin staining 
was doneto quantify actin polymerization. c) Flow cytometry data was 
normalized to Ci cells and presented as the mean ±standard deviation of three 
independent experiments. 
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Plcγ1 and Grb2 expression influence survival outcome in ovarian cancer 
patients 
Having shown that Plcγ1 and Grb2 competition for FGFR2 binding dictate cell 
invasion and migration, we next investigated the effect of this competition on 
the survival outcome of cancer patients. Kaplan-Meier survival curves 
generated from ovarian cancer patients revealed that high level of FGFR2/Plcγ1 
was associated  with worse survival compared with low level of FGFR2/Plcγ1, 
respectively. Also, high Grb2 /low FGFR2 /low Plcγ1 level profile was 
associated with better survival in ovarian cancer patients compared to low Grb2 
/high  FGFR2 /high Plcγ1 level profile (Fig 3.10). 
In summary, Plcγ1 binding to FGFR2 when the Grb2 concentration is low 
increases cell motility and invasion, which are prerequisites to metastasis.  
Therefore, Grb2 and Plcγ1 protein concentrations may dictate metastatic 
potential, which may impact patient survival outcome. 
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Fig 3.10 High Grb2 and low FGFR2 and Plcγ1 expression profile is 
associated with better survival in ovarian cancer. Data from online TCGA 
and Tothill databases was used to generate Kaplan-Meier overall survival (OS) 
curves of patients with ovarian cancer. mRNA levels of FGFR2, Plcγ1, and 
Grb2 (presented individually or in different combinations)  were determined from 
microarray studies. Cut-off values and statistical significance determined by 
Student’s t-test are shown for each survival curve.  
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Chapter Four: PTEN-mediated Akt activation is 
dictated by Grb2 expression level 
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Background 
The Akt pathway is an important oncogenic pathway that promotes cell growth, 
survival, and glucose metabolism (22). The activity of this pathway is dependent 
on plasma membrane phospholipid constituents. Class I PI3Ks phosphorylate 
plasma membrane-localized PIP2 to produce PIP3. PIP3 binds to Akt to induce 
Akt activation (52,53). Akt activity is counteracted by PTEN, a lipid phosphatase 
that hydrolyzes PIP3 to PIP2 (54,55). The balance of PI3K and PTEN activity in 
controlling the abundance of phospholipids is important in cellular response.  
It is important to note that PTEN activation is only possible in the presence of a 
subset of PIPs such as PIP and PIP2. Recent studies have established that the 
binding of PIP2 to the N-terminus of PTEN (56) induces a conformational 
change (18) that upregulates phosphatase activity (57). PTEN phosphorylation 
leads to a closed conformation that inhibits phosphatase activity (58). 
In the previous chapters, the expression level of Grb2 in cells was shown to 
have a profound effect on Plcγ1 activity in non-stimulated cells. In cells depleted 
of Grb2 (G2i cells), Plcγ1 binding to FGFR2 results in Plcγ1 activation and 
subsequent PIP2 turnover. 
In this chapter, Plcγ1-mediated reduction in PIP2 concentration due to depleted 
Grb2 concentration is shown to down-regulate PTEN activity, resulting in PIP3 
accumulation. This leads to membrane-recruitment and activation of the Akt 
signaling pathway, which enhances cell proliferation (Fig 4.1). Thus, fluctuations 
in the concentrations of two competing non-phosphorylated proteins via their 
SH3 domains can affect cell fate by modulating PIP2 level.
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Fig 4.1 Basal stage competition between Grb2 and Plcγ1 controls PTEN-
mediated Akt activation. (top) In cells with high levels of Grb2, Plcγ1 is unable 
to bind to FGFR2 and thus, membrane-localized PIP2 is not depleted. PIP2 
stabilizes PTEN activity. (bottom) In the absence of Grb2, Plcγ1 is able to bind 
to FGFR2. Activated Plcγ1 hydrolyzes PIP2. Depletion of PIP2 destabilizes 
PTEN activity. Loss of PTEN function leads to the accumulation of PIP3, which 
binds to Akt to increase its phosphorylation and activity. 
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Methods 
Reagents 
FGFR2 (C-17) and Grb2 (C-23) antibody and scrambled shRNA, Grb2 shRNA, 
and Plcγ1 shRNAs were purchased from Santa Cruz Biotechnology. Anti-GFP 
and anti-RFP rabbit antibodies were purchased from Rockland 
Immunochemicals. U0126 (MEK1/2 inhibitor), phospho(Ser241)-PDK1, 
wortmannin (PI3K inhibitor), β-actin antibody, anti-mouse and anti-rabbit 
secondary antibodies, Akt, phospho(Ser473)-Akt, phospho(Thr308)-Akt, phospho-
PTEN, and phospho(Ser21/9)-GSK-3α/β (37F11) were purchased from Cell 
Signaling Technology. Plcγ1 mouse antibody was purchased from BD 
Biosciences. Puromycin dihydrochloride, selection antibiotic, was purchased 
from Invitrogen. Metafectene transfection reagent was purchased from Biontex-
USA. The Plc inhibitor U73122 was purchased from Sigma-Aldrich. The PTEN 
inhibitor SF 1670 was purchased from Echelon Biosciences. 
 
Cell culture 
Parental and FGFR2-overexpressing HEK293T cells were cultured in DMEM 
supplemented with 10% (vol/vol) FBS and 1% antibiotic/antimycotic (Lonza) in a 
humidified incubator at 37°C with 10% CO2. Ci, G2i, and Pγi cells were 
established as described in Chapter Two. 
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Western Blot Analysis 
Cultured cells were grown in 10-cm dishes and serum starved overnight. Cells 
were left untreated or treated with 9 µM U73122, 1 µm wortmannin, or 10 µM 
U0126 for 2 h. Cells were also treated with 500 nM SF 1670 for 30 min. Cells 
were lysed with Hepes lysis buffer (50 mM Hepes, pH 7.5, 1% [vol/vol] igepal-
C630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 1 mM sodium 
orthovanadate, 10% [vol/vol] glycerol, 50 mM NaCl, 1 mM PMSF, and Protease 
Inhibitor Cocktail Set III (EMD Millipore) . Protein concentration was quantified 
at 595 nm, and 50 µg of total proteins was used for every blot.  
 
Kinase Assay 
Cell lysates were collected and incubated with total Akt antibody overnight. 
Protein A/G Plus-Agarose (Santa Cruz Biotechnology) was used for 
immunoprecipitation experiments according to the manufacturer’s instructions. 
Cell lysate bound to immobilized antibody waswashed with 3x lysis buffer , 
suspended in 50µl 1x kinase buffer (Cell Signaling Technology), and incubated 
with 10 mM ATP (1 µl)and Akt substrate (1 µl;purified GSK-3 fusion protein [Cell 
Signaling Technology]) for 30 min at 30°C.The reaction was terminated by 
adding sample loading buffer and heating the samples. Samples (20 µl) were 
loaded onto a gel and subjected to western blot analysis. 
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Soft Agar Assay  
One milliliter of 1% FBS DMEM containing 0.75% agar was used as the bottom 
layer. 0.6 x104 of indicated cells were cast in agar as a single cell suspension in 
1 ml DMEM (upper layer).  Cells were left to grow for 8 days. 500 ml of DMEM 
with 1% FBS (with or without inhibitors (4 µM U73122/100 nM Wortmannin/5 
µM U0126/150 nM SF 1670) was added to the wells once a week.  
Drugs of interest were added to the underlay and overlay agar medium, as well 
as the liquid top layer which was initiated one day after seeding the cells. 
Concentrations were optimized so as to avoid cell death over the prolonged 
period of 8 days. Every experiment was performed in triplicates. Colonies were 
counted and averaged in different microscopic fields then normalized against 
control cells in serum starvation medium. Error bars on the graph represent the 
standard deviation calculated. 
 
Phosphatase Assay 
PIP2 and Ptdser (both from Avanti Polar Lipids,INC) were prepared to a final 
concentration of 2 mg/ml and 5 mg/ml respectively in chloroform:methanol: 
10mM HCl (20:9:1). The resuspension buffer was composed of 20 mM HEPES 
(pH 7.5), 1mM MgCl2, and 1 mM EGTA. Kinase buffer consisted of 400 mM 
HEPES (pH 7.8), 100mM MgCl2, and 20 mM EGTA.  
For substrate preparation, 16.8 µl PIP2 stock and 6 µl Ptdser stock were mixed, 
evaporated, resuspended in 500 µl resuspension buffer, sonicated for 1 min at 
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15% on ice. Eighteen microliters water, 2 µl cold ATP, 5 µl purified PI3K 
(Echelon), 50 µl PIP2/Ptdser, and 20 µl γ32P-ATP were mixed and incubated at 
room temperature overnight. The reaction was stopped by adding 100 µl of 1M 
HCl and 10 µl Ptdser.Ptdser was preparing the carrier lipid at a concentration of 
5 mg/ml,drying out 40 µl , then resuspending in 400 µl  resuspension buffer and 
sonicating)+ chloroform:methanol (1:2) + 0.5N NaCl in 0.1 N HCl. The obtained 
ratio was: 0.1:0.3:0.1. 
The reaction was vortexed and centrifuged for 5 min at 10,000 x g. The bottom 
layer was dried and resuspended in 500 µl of lipid resuspension buffer. 145 µl 
of obtained solution was added to cell lysates or 55 µl was added to purified 
proteins reaction. In each case, 30 µl of substrate was utilized. This was 
followed by 2-h incubation at 37°C. 
For cell lysate reaction,1M HCl, Ptdser, Chloroform:Methanol, 0.5N NaCl in 0.1 
HCl were added as: 85 µl,40 µl, 900 µl, 300 µl.For purified protein reaction, 55 
µl,10 µl, 450 µl, 150 µl of each reagent was used. Bottom phase was used for 
TLC. 
 
PI3K Assay 
2 mg/ml of cold PIP2 and 5 mg/ml of Ptdser were each dissolved in 
chloroform:methanol: 10 mM HCl (20:9:1). 20 µl of Ptdser mixed with 50 µl PIP2 
were mixed, evaporated, and resuspended in 300 µl of resuspension buffer 
then sonicated for 1 minute at 15% on ice. 200 µl of kinase buffer was added, 
along with 32 µl cold 2.5 mM ATP (to a final concentration of 160 µM) and 1 µl 
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γ32P ATP. 100 µl  substrate was mixed with 100 µl of cell lysate and incubated 
for 2 hours at 37°C. Reaction was stopped by adding 5 µl Ptdser (made by 
preparing the carrier lipid at a concentration of 5 mg/ml,drying out 40 µl , then 
resuspending in 1000 µl  resuspension buffer and sonicating). For each 
reaction,1M HCl, chloroform:methanol, 0.5N NaCl in 0.1 HCl were added as: 
100 µl, 900 µl, 300 µl. Reaction was centrifuged for 3 minutes. Bottom phase 
was used for TLC analysis. 
 
Microscopy 
HEK293T cells (Ci and G2i) stable expressing GFP-FGFR2 were transfected 
with an empty mCherry vector or Akt-PH-mcherry using metafectene fllowing 
manufacturer’s instructions. Success of transfection was detected via western 
blot analysis. Serum starved cells on glass coverslips were fixed with 4% 
(wt/vol) paraformaldehyde, pH 8.0 for 20 minutes when transfected with the 
domains. Cells were then washed with PBS, to be mounted onto a slide with 
mounting buffer (0.1% p-phenylenediamine/75% glycerol in PBS). Imaging was 
performed using a confocal microscope (model SP5; Leica) to detect 
colocalization between mcherry tagged construct and GFP used as a 
membrane marker to indicate membrane localization of the domain. 
 
RPPA Analysis and Heat Map Generation 
Cell lysates (Ci and G2i cells in triplicates) were submitted to the RPPA core 
facility. Based on the technical information provided by the facility, “the samples 
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were two-fold-serial diluted for 5 dilutions and arrayed on nitrocellulose-coated 
slide in 11x11 format. Samples were probed with antibodies by CSA 
amplification approach and visualized by DAB colorimetric reaction. Slides were 
then scanned on a flatbed scanner to produce 16-bit tiff image. Spots from tiff 
images were identified and the density was quantified by MicroVigene. Relative 
protein levels for each sample were determined by interpolation of each dilution 
curves from the "standard curve" (supercurve) of the slide (antibody). 
Supercurve is constructed by a script in R written by Bioinformatics.  These 
values (given as Log2 values) are defined as Supercurve Log2 (Raw) value". All 
the data points were normalized for protein loading and transformed to linear 
value designated as "Linear after normalization". The linear values were used 
for "bar graph" generation were the error bars indicate the calculated standard 
deviation. Heatmaps for an Unsupervised Hierarchical cluster (unsupervised on 
both antibodies and samples (data not shown)) and an antibody unsupervised 
but samples in order were provided. The heatmap included was generated in 
Cluster 3.0 (http://www.eisenlab.org/eisen/) as a hierarchical cluster using 
Pearson Correlation and a center metric. The resulting heatmap was visualized 
in Treeview {http://www.eisenlab.org/eisen/) and presented as a high resolution 
.bmp format.” 
 
Cell fractionation 
HEK293T cells (Ci and G2i) were serum starved overnight and then washed 3X 
with PBS. Subcellular Protein Fractionation Kit for Cultured Cells (Thermo 
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SCIENTIFIC) was used according to manufaturer’s instructions. Following 
protein quantification, western blot analysis was performed where FGFR2 was 
used as a membrane marker, and β-actin as cytoplasmic marker. 
 
TCGA analysis 
We downloaded and analyzed data publicly available from the Cancer Genome 
Atlas Project (TCGA; http://tcga-data.nci.nih.gov/) for eleven tumor types: 
bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA),  colon 
adenocarcinoma (COAD), glioblastoma multiforme (GBM), head and neck 
squamous cell carcinoma (HNSC), kidney clear cell carcinoma (KIRC), lung 
adenocarcinona (LUAD), lung squamous cell carcinoma (LUSC), ovarian 
serous cystadenocarcinoma (OV), thyroid carcinoma (THCA), uterine corpus 
endometrial carcinoma (UCEC).  Level 3 Illumina RNASeq (versions 1 and 2), 
respectively RPPA data were used  to extract mRNA and protein expression 
levels. Analyses were performed in R (version 2.14.2) (http:///www.r-
project.org/) and the statistical significance was defined as a p-value less 0.05.  
The Spearman's rank-order correlation test was applied to measure the 
strength of the association between mRNA and RPPA levels across tumor 
types.  A box-and-whisker plot was used to visualize RPPA levels across tumor 
types.  
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Molecular cloning 
Empty mCherry vector was used in the experiments along with Akt-PH domain 
cloned in mCherry vector. The kinase dead cytoplasmic portion of FGFR2 
(residues 413-821) was generated through a point mutation (K517I) in the 
catalytic region. Grb2 was also cloned in a myc tagged pCDNA3.1 mammalian 
expression vector. 
 
Protein expression and purification 
6Xhistidine-tagged constructs of FGFR2, and Grb2 were expressed and purified 
from E. coli as previously described (3).  
 
Measurement of PIP3 level in whole cells 
Measurement of steady-state content of phosphatidylinositol 3,4,5-
bisphosphate (PtdIns(3,4,5)P3) was performed in  [3H]myo-inositol uniformly 
radiolabelled cells. HEK293T cells were prelabeled with myo-[2-3H(N)]inositol 
(1µCi/ml)  (Perkin-Elmer) for  24 h in inositol and serum-free DMEM medium 
and then washed with PBS. After labeling, the cells were harvested, washed, 
and subjected to lipid extraction and TLC analysis. 
 
Lipid extraction and TLC Analysis 
The cell pellet was resuspended in 0.2 ml of 0.5 N NaCl in 0.1 N HCl and 0.6 ml 
chloroform: methanol (1:2) was added and the suspension was vigorously 
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vortexed for 30 min. 0.2 ml of 0.5 N NaCl in 0.1 N HCl was added followed by 
vortexing for 10 min. After 5 min of centrifugation on Eppendorf Table 
Centrifuge, upper water-methanol phase was discarded and lower chloroform 
lipid phase was transferred to an Eppendorf tube.  
Lipids extracts were used in thin layer chromatography (TLC) analysis. 25,000 
cpm aliquots were brought to same volume with chloroform. The phospholipids 
were analyzed by silica gel TLC after separation by one-dimensional TLC on 
potassium oxalate impregnated silica gel plates using a solvent system 
containing chloroform/methanol/ammonium hydroxide/water (57:50:4:11, 
v/v/v/v) to separate PtdIns(4,5)P2, PtdIns(3,5)P2 , and PtdIns(3,4,5)P3   from 
one another. 
20 cm high-performance Partisil LK5 silica gel precoated TLC plates with a 
concentration-zone (Whatman Inc. Clifton, NJ) were impregnated for 1 min in 
1.2 % (w/v) potassium oxalate in methanol-water (2:3). After air drying, the 
plates were desiccated at 100°C for 60 min before use. Radiolabeled lipids 
were visualized and quantified using a Personal Molecular ImagerTM FX (Bio-
Rad Laboratories). Stored images were processed and quantified using 
Quantity One software for scanning and analysis of the captured Phosphor 
images (Bio-Rad Laboratories). Phospholipid content is expressed as mol% of 
total phospholipid based on the pixel intensity of the captured signal on 
Phosphor screen generated by the radiolabeled spots on the TLC plate.  
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Xenograft mouse model and magnetic resonance imaging (MRI) 
Adult female nude mice were injected with 0.5 x106 PCi, PG2i, PPγi, Ci, G2i , 
and Pγi cells in PBS (4 mice per group). Injections were done subcutaneously 
in the right flank of the animal. After 60 days and for MRI imaging, mice were 
scanned on a 4.7T Biospec USR47/40 small animal imaging system (Bruker 
Biospin MRI, Inc., Billerica, MA) with a 35-mm linear volume resonator and 60-
mm micro-imaging gradients. A three-plane FLASH imaging sequence was 
used to confirm animal positioning, and coronal and axial T2-weighted RARE 
images (TE/TR 57/3000ms, FOV 4cm × 3cm, matrix 256 × 192, RARE factor 
12) were used for tumor localization and volume measurement. 
For tumor volume calculation ROI was created in imageJ software that 
surrounds tumors in the axial sections (for every slice). The areas of the ROIs is 
in mm2. ROI areas were then summed up and multiplied by the slice thickness 
(0.75 mm for all of the scans). This is the volume of tumor within the image 
slices. To account for the slice gap between adjacent slices (0.25 mm for all of 
the scans), the mean of the ROI areas for each pair of adjacent slices was 
computed then the sum of these means is multiplied by 0.25 mm to get an 
estimate of the tumor volume between slices. The tumor volume estimates were 
then added within slices and between slices to get the total tumor volume in 
mm3. Tumor volumes for mice in each group were averaged. 
Following imaging, mice were sacrificed, tumors were weighed and weights 
were averaged in each group and plotted as bar graph where the standard 
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deviation of the mean is denoted by error bars. Half of each tumor was used for 
western blot analysis and the other half for immunohistochemistry (IHC). 
Proteins used in western blot analysis were extracted via sonication up to 30 
minutes on ice at low setting (to efficiently separate the lipid fraction found on 
top of protein layer). This was followed by centrifugation at 13000 rpm for 15 
minutes at 4°C. The supernatant containing the proteins was transfered to a 
new tube. IHC was performed on paraffin embedded tumors sectioned at 5 µm. 
Hematoxylin and eosin staining along with pAkt (serine 473) antibody staining 
were performed on rehydrated samples followed by visualization. This was 
done using automated Leica Bond III- autostainer (Department of Veterinary 
Medicine & Surgery at MD Anderson Cancer Center).  For that, slides were 
baked at 60⁰C for 30 minutes then the temperature was increased to 72⁰C. 
Slides were then rinsed 3 times with Bond Dewax followed by absolute alcohol 
and Bond Wash. Temperature was then increased to 100⁰C, and Bond ER 
Solution 1 (ph6) was applied and incubated for 30 minutes. Slides were rinsed 
with Bond Wash and temperature was allowed to come down to room 
temperature.  Antibody Phospho-Akt (Ser473) (D9E) XP Rabbit mAb #4060 
(Cell Signaling Technology) was applied at 1:50 dilution and incubated for 15 
minutes at room temperature followed by rinsing with Bond Wash. Post Primary 
was applied and incubated for 8 minutes then slides were again rinsed with 
Bond Wash. Bond Polymer was applied and incubated for 8 minutes followed 
by rinsing with Bond Wash 2 times then DIH₂O. Peroxide Block was applied and 
incubated for 5 minutes then rinsed with Bond Wash 4 times then with DIH₂O. 
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DAB was applied and incubated for 10 minutes then rinsed with DIH₂O 3 times. 
Hematoxylin was applied and incubated for 7 minutes then rinsed with Bond 
Wash. Slides were then removed from Leica Bond III and rinsed with DIH₂O 4 
times. They were then dehydrated in graded alcohols and xylene then 
coverslipped with ClearMount from American MasterTech using Leica CV5030 
coverslipper. 
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Results 
Grb2 depletion increases cell proliferation 
In non-stimulated FGFR2-over-expressing HEK293T G2i cells, the number and 
size of anchorage-independent colonies was dramatically increased compared 
with Ci cells (Figure 4.2a,b,c,d). Furthermore, colony formation was abrogated 
in parental HEK293T cells, which express low levels of endogenous FGFR2 
(Figure 4.2a,e). Therefore, colony formation was associated with constitutive 
Grb2-FGFR2 complex formation (2), which inhibits protein recruitment to the 
receptor C-terminus (59). Anchorage-independent growth was independent of 
the MAPK pathway as evidenced by the lack of effect of the potent MAPK 
inhibitor U0126 on colony formation (Figure 4.2b,c and Fig4.3a,b).  
Because Grb2 is a key component of the RTK-mediated up-regulation of the 
MAPK pathway, which is linked to proliferative response, increased colony 
growth in the absence of Grb2 was a surprising observation. The absence of a 
MAPK proliferative signal strongly implicated PI3K/Akt pathway activation in the 
observed colony formation. 
FGFR2-mediated anchorage-independent growth was dependent on Plcγ1 
because colony formation was largely abrogated in G2i cells treated with the 
phospholipase inhibitor U73122 (Figure 4.2b,c). Furthermore, Plcγ1 
knockdown in GFP-FGFR2-over-expressing HEK293T (Pγi) cells and parental 
cells stably transfected with empty GFP vector (PPγi) inhibited colony formation 
(Fig4.3c-f). Thus, anchorage-independent growth was specifically dependent 
on high FGFR2, low Grb2, and high Plcγ1 expression levels.  
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Fig 4.2: FGFR2 is required for Akt-dependent colony formation in Grb2 
knockdown cells.a) Parental and FGFR2-overexpressing HEK293T cells were 
transfected with scrambled and Grb2 shRNAs to generate PCi and PG2i and Ci 
and G2i cell lines, respectively. Western blot analysis was done to determine 
the efficiency of FGFR2 transfection and Grb2 knockdown. Arbitrary numbers 
on the blot represent densitometric analysis performed via Image J software.b) 
Soft agar assay was used to determine anchorage-independent growth in Ci 
and G2i cells. The lower layer consisted of DMEM/agar containing 1% FBS. 
The upper layer consisted of a single cell suspension (0.6 x104)in serum-free 
DMEM/agar.Colony formation was determined after 8 d. DMEM containing 1% 
FBS with or without the indicated inhibitors was added to the wells once a 
week. c) The number of colonies was counted in different microscopic fields 
and normalized to Ci cells in serum-free DMEM. Values shown represent the 
mean ± standard deviation of three independent experiments. d) Magnification 
of colony formation in GFP-FGFR2-overexpressing Ci andG2i cells.e) 
Anchorage-independent growth was determined in parental HEK293Tcells 
using soft agar assay as described in b.  
 
 
 
 
e 
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Fig 4.3: Plcγ1 is required for FGFR2 to induce Akt-dependent colony 
formation. a) Soft agar assay was used to evaluate anchorage-independent 
growth in Ci and G2i cells. The lower layer consisted of DMEM/agar containing 
1% FBS. The upper layer consisted of a single cell suspension (0.6 x104) in 
serum-free DMEM/agar. After 8 days, DMEM containing 1% FBS with or 
without the indicated inhibitors was added to the wells once a week. Pictures of 
the entire well were taken.b)The number of colonies was counted and 
normalized to Ci cells in serum-free DMEM. Values shown represent the mean 
± standard deviation of three independent experiments.c) Parental and FGFR2-
overexpressing HEK293T cells were transfected with scrambled, Grb2 and 
Plcγ1 shRNAs to generate PCi, PG2i, and PPγi and Ci, G2i, and Pγi cell lines, 
respectively. The efficiency of Grb2 andPlcγ1 knockdown and FGFR2 
transfection was confirmed by western blot analysis.d) Soft agar assay was 
done to evaluate anchorage-independent growth in Ci, G2i, Pγi, PCi, PG2i, and 
PPγi cells as described in a.e) The number of colonies wascounted and 
normalized to PCi cells in DMEM containing 1% serum. Values shown 
represent the mean ± standard deviation of three independent experiments.f) 
Magnification (5x) of colony formation in one microscopic field for Ci, G2i, Pγi, 
PCi, PG2i, and PPγi cells. 
 
 
PI3K activity is unaffected in Grb2-depleted cells 
We previously reported that Grb2 depletion in non-stimulated cells up-regulated 
Plcγ1, leading to turnover of plasma membrane PIP2 (59). In addition to Plcγ1, 
cellular PIP2 concentration of is regulated by PI3K and PTEN. Therefore, we 
determined whether PI3K and PTEN were involved in the proliferative cellular 
response in non-stimulated G2i cells.To do this, reverse phase protein array 
(RPPA) was used to assess the expression and/or phosphorylation of select 
proteins and effectors of the PI3K and PTEN pathways in non-stimulated Ci and 
G2i cells (Fig 4.4a). A comprehensive heat map is shown in Fig 4.5 andTable 
4.1. The expression level of the p85 and p110 subunits of PI3K were not 
appreciably changed between G2i and Ci cell lines (Fig 4.4b). The addition of 
the PI3K inhibitor wortmannin reduced colony formation in Ci and G2i cells, 
suggesting the presence of constitutive PI3K activity in both cell lines (Fig 4.2 
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b,c). PI3K converts PIP2to PIP3; therefore, the constitutive PI3K activity in G2i 
cells suggested that the combined activities of Plcγ1 and PI3K deplete the pool 
of PIP2to reduce the PIP2/PIP3 ratio (see schematic in Fig 4.1).  
 
 
 
 
a 
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Fig 4.4 Increased phosphorylation of Akt in G2i cells is independent of 
PI3K and PTEN expression. a) Heat map of the log2 values of triplicate 
samples from Ci and G2i cells. The heat map was generated from the original 
heat map provided by the facility using theR console statistical package.b-i) 
Linear values normalized to control cells were used to construct bar graphs of 
the ratios of phosphorylated protein to total protein, phosphorylated protein to 
actin, and total protein to actin. 
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Fig 4.5 Phosphorylation levels of Akt and its downstream effectors is 
higher in G2i cells compared with Ci cells. RPPA heat map showing the 
phosphorylation levels of Akt and its downstream effectors in G2i and Ci cells. 
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Table 4.1 Linearized values obtained from the RPPA analysis of G2i and Ci 
cells. Linearized values of the expression and/or phosphorylation of PTEN and 
Akt and their downstream effectorsfrom the RPPA analysis of G2i and Ci 
cellsare shown. Linear values were averaged, normalized tocontrol cells, and 
used to generate bar graphs. 
 
 
 
In Ci cells, the pool of PIP2 is not as severely affected because Plcγ1 is inhibited 
in the presence of Grb2. Addition of the PI3K-specific inhibitor wortmannin 
reduced PIP3 production in Ci cells; therefore, PI3K contributed in part to PIP2 
depletion (Fig 4.6a,b). Intracellular level of PIP3 in myo-[2-3H(N)]inositol-labeled 
Ci and G2i cells was also measured in Fig 4.6c and it appeared to increase 
upon knocking down Grb2. 
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Fig 4.6 PIP3 to PIP2 ratio is higher in G2i cells compared with Ci cells and 
is independent of PI3K p85 phosphorylation level and activity. a) PI3K 
kinase assay was performed on cell lysates obtained from untreated 
andwortmannin-treated Ci and G2i cells. Cell lysates were incubated32P-labeled 
ATP and unlabeled PIP2, PI3K substrate. PIP3 product and remaining PIP2 
substrate were separated by TLC. b) PI3K kinase assay data was volume 
adjusted (pixel percentage and normalized to untreated control cells were 
obtained in duplicates visualized and quantified for adjusted volume. c) Lipid 
was extracted from cell lysates obtained from myo-[2-3H(N)]inositol-labeled Ci 
and G2i cells . PIP3 was identified by TLC based on the Rf value and quantified 
at the pixel level. 
 
PTEN activity is down-regulated in Grb2-depleted cells 
The effect of PI3K on PIP3 production is reversed by PTEN phosphatase 
activity, which restores membrane PIP2 concentrations. Incubation of G2i cell 
lysates with 32P-PIP3 inhibited the ability of PTEN to restore PI(4,5)P2 levels, 
resulting in a dramatic reductioninPIP2/PIP3ratio (Fig 4.7a). RPPA analysis 
showed that PTEN expression was not significantly different between G2i and 
Ci cells (Fig 4.4c). Because PTEN binding to PIP2 is required to induce its 
activity, the reduction in the PIP2 pool resulting from combined Plcγ1 and PI3K 
activitiesin G2i cells may affect the ability of PTEN to turnover PIP3. In other 
words, PIP2 depletion negatively regulates PTEN, resulting in the accumulation 
of PIP3.To demonstrate that the increase in PIP3 in G2i cells is dependent on 
PTEN, cells were treated with the PTEN inhibitor SF1670. PTEN inhibition 
using SF1670 reduced PIP2/PIP3 ratio (Fig4.7a). Furthermore, inhibition of 
Plcγ1 using U73122 reduced PIP2 concentration and PIP2/PIP3 in G2i cells to 
that of Ci cells (Fig 4.7a). To determine whether Plcγ1 affects PTEN 
phosphatase, Ci cells were either left untransfected or transfected with wild-type 
Plcγ1. PTEN activity was lower in Plcγ1-transfected Ci cells than in 
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untransfected Ci cells (Fig 4.7b). Together, these findings indicated that Plcγ1-
mediated PIP2 depletion disables PTEN activity. 
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Fig 4.7 Plcγ1-mediated PIP2 depletion negatively regulates PTEN activity 
in G2i cells.a) Cell lysates were obtained from cells treated with the Plcγ1 
inhibitor U73122 or the PTEN inhibitor. Cell lysates from untreated cells served 
as a control. Cell lysates were incubated with 32P-labeled PIP3, and TLC was 
used to separate and identify PIP2 and PIP3 (top panel). PIP2/PIP3ratioswere 
generated from the pixel data and are presented as the mean ± standard 
deviation of three independent experiments (bottompanel). *p ≤ 0.05 and **p≤ 
0.01 (Student’s t-test).(b) Ci cells were left untransfected or transfected with 
Plcγ1.Cell lysates were incubated with 32P-labeled PIP3, followed by TLC 
analysis and PIP3/PIP2 ratio quantification as described in a. c,d) Various 
combinations of purified proteins including Plcγ1, Grb2, PTEN, and kinase dead 
(KD) FGFR2wereincubated with 32P-labeled PIP3, followed by TLC analysis and 
PIP3/PIP2 ratio quantification as described in a. Values shown represent the 
mean ± standard deviation of triplicatesamples. e,f) Purified PTEN was 
incubated with Ptdser and [32P]-PI (3,4,5)P3 in the presence or absence of 33 
µg/µl cold PIP2. 32P-PIP2 and PIP3 were separated by TLC, visualized, and 
quantified at the pixel level (top panel). PIP2/PIP3 ratios were generated from 
the pixel data and are presented as the mean ± standard deviation of two 
independent experiments (bottom panel).  
 
 
Inhibition of PTEN using SF1670 slightly increased colony formation in G2i cells 
(Fig 4.2b,c and Fig 4.3a,b). As expected, the effect of PTEN inhibition on 
colony formation was more dramatic in Ci cells. This is because the 
suppressive activity of PTEN is abrogated in Ci cells. Our finding corroborates 
the fact that, in normal cells, constitutive PTEN activation restores plasma 
membrane PIP2.  
To further examine the relationship between Plcγ1 and PTEN in vivo, we 
utilized purified proteins in an in vitro reconstitution assay. KD FGFR2 and 
Plcγ1 were added to PTEN in the presence and absence of Grb2. PIP3 
accumulation was more dramatic in the absence of Grb2 compared with the 
presence of Grb2 (Fig4.7c, d) Thus, the increased turnover of PIP2 by Plcγ1 in 
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the absence of Grb2 decreases PTEN activity and results in the accumulation 
of PIP3. 
To confirm that PI(4,5)P2 is needed for the stabilization of PTEN activity, purified 
PTEN was incubated with 32P-PIP3 and Ptdser in the absence and presence of 
cold PIP2.The activity of PTEN was dramatically enhanced in the presence of 
PIP2 (Fig4.7e,f). 
 
Akt is upregulated in Grb2-depleted cells 
The inactivity of PTEN in G2i cells results in the accumulation of PIP3, on which 
Akt binds. Upon binding to the membrane, Akt is phosphorylated and 
downstream signaling ensues. Accumulation of PIP3 with respect to PIP2 in the 
absence of Grb2 is reflected in the increased expression of phosphorylated Akt 
(pAkt) (Fig 4.3a,d) and its downstream effectors including mtor glycogen 
synthase kinase 3 (Gsk3; Ser21; Fig 4.3f), p70 S6 kinase (p70S6K; Thr389, 
Ser235, and Ser240; Fig 4.3g), S6 ribosomal protein (Ser235/236 and 
Ser240/244; Fig 4.3h), and proline-rich Akt substrate 40 (Pras; Thr246; Fig 
4.3i) in G2i cells compared with Ci cells. Thus, Plcγ1 activation in the absence 
of Grb2 indirectly increased Akt activation and downstream signaling in non-
stimulated HEK293T cells.  
Elevated levels of pAkt (S473 and T308) were observed in G2i cells compared 
with Ci cells (Fig 4.8a). Treatment of G2i cells with the PTEN inhibitor SF1670 
increased Akt phosphorylation.Furthermore, Akt phosphorylation was inhibited 
by the forced expression of Grb2 in G2i cells (Fig 4.8b).  Together, these 
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findings demonstrated that Akt phosphorylation was dependent on PTEN. 
Interestingly, PTEN phosphorylation was increased in G2i cells compared with 
Ci cells, whereas Grb2 overexpression decreased PTEN phosphorylation in G2i 
cells (Fig 4.8b).  
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Fig 4.8 PTEN-mediated Akt phosphorylation and activity is dependent on 
Grb2 and Plcγ1 concentrations. a)Western blot analysis was done to 
determine the expression of pAkt (Ser473 and T308) in cell lysates obtained 
from untreated and SF1670-treated Ci and G2i cells.b) Western blot analysis 
was done to determine the expression of pAkt (Ser473) and phosphorylated 
PTEN (S380/T382/383) in cell lysates obtained from Ci, G2i, and Grb2 knock in 
G2i cells.c) Western blot analysis was done to determine the expression of total 
Plcγ1, Grb2, and pAkt (Ser473) in Ci, G2i, and Pγi cells.d) Western blot 
analysis was done to determine the expression of pAkt (Ser473 and T308) in 
cell lysates obtained fromuntreated and U73122-treated Ci and G2i cells.e) 
Western blot analysis was done to determine the expression of phosphorylated 
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PDK1 (Ser241) in cell lysates obtained from Ci and G2i cells.f) Ci and G2i cells 
were left untreated or treated with the indicated inhibitors. Akt kinase assay was 
performed on the cell lysates. Western blot analysis was used to detect the 
effect of the inhibitors on kinase activity.g) Akt kinase assay was performed on 
Ci, G2i, and Pγi cell lysates. In all western blot analyses, β-actin was used as a 
loading control. 
 
Phosphorylation of PTEN inhibits its phosphatase activity, thereby facilitating 
PIP3 accumulation and Akt recruitment. Inhibition of Akt using Akt inhibitor VIII 
reversed the Grb2-dependent Akt phosphorylation (Fig 4.9a) and inhibited 
colony formation (Fig 4.2b,c and Fig 4.3a,b).In addition, we demonstrated that 
Akt phosphorylation in G2i cells was linked to PI3K activity because, in the 
presence of wortmannin, pAkt was decreased (Fig 4.9b) even though PI3K 
activity wassimilar between Ci and G2i cells. Conversely, Akt phosphorylation 
was independent of MAPK pathway activation as demonstrated by the 
negligible effect of the MEK inhibitor U0126 on pAkt levels (Fig 4.9c).   
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Fig 4.9 Akt phosphorylation is PI3K dependent and MAPK independent in 
Ci and G2i cells. a) Western blot analysis was done to determine the 
expression of pAkt (Ser473) in cell lysates obtained from untreated andAkt 
inhibitor VIII-treatedCi and G2i cells. b) Western blot analysis was done to 
determine the expression of pAkt (Ser473 and T308) in cell lysates obtained 
from untreated and wortmannin-treated Ci and G2i cells.c) Western blot 
analysis was done to determine the expression of phosphorylated Erk1/2 and 
pAkt (S473) in untreated and U0126 (MEK1/2 inhibitor)-treated Ci and G2i 
cells.β-actin was used as a loading control in all western blot analyses. 
 
 
To demonstrate that Akt phosphorylation was dependent on Plcγ1, Plcγ1 was 
inhibited using Plcγ1 knockdown (Pγi) cells and U73122. Akt phosphorylation 
was decreased in Pyi cells (Fig 4.8c) and U73122-treated cells (Fig 4.8d). 
These data further support that the reduction in PIP2 concentration as a result of 
Plcγ1 activity inactivates PTEN, resulting in Akt activation.  
Since PDK1 protein which phosphorylates Akt on T308 also binds to PIP3 
resulting in phosphorylation and activation, we decided to study its 
phosphorylation status in Ci and G2i cells (Fig 4.8e). As expected, its 
phosphorylation level is higher in G2i cells compared to Ci cells. 
To confirm that the increase in Akt phosphorylation level is accompanied by an 
increase in its activity, we immobilized total Akt from Ci and G2i cells on A/G 
agarose beads and incubated them with purified GSK (Akt substrate) in the 
presence of ATP. This kinase assay (Fig 4.8f, 4.8g) showed an increase in Akt 
activity in G2i cells compare to Ci and Pγi cells. U73122, and Wortmannin 
decreased the activity of Akt but U0126 had little or no effect unlike SF1670, 
which enhanced the activity. These results match the ones obtained for the 
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phosphorylation status of this kinase. Thus, Plcγ1 dependent decrease in PTEN 
activity in G2i cells is reflected in a decrease in the activity of Akt. 
To confirm that the constitutive activation of Akt is dependent on the recruitment 
of the kinase to the plasma membrane in G2i cells we used HEK293T cells 
over-expressing N-terminally GFP-tagged FGFR2. Since in non-stimulated cells 
FGFR2 is membrane localized this provides a clear marker for the cell 
membrane.  
We also expressed the PH domain of Akt (Akt-PH) with a mCherry fluorescent 
fusion protein tag (an empty mCherry vector was used as a control; Fig 4.10a). 
The PH domain has previously been reported to be responsible for the 
recruitment of Akt to the membrane on stimulation. In Ci cells there is no co-
localization of the fluorescent tags reflecting the lack of recruitment of Akt-PH to 
the membrane (Fig 4.10b), however in the G2i cells clear co-localization of Akt-
PH to the membrane is observed. This is consistent with the observation that 
Akt translocates to the PIP3-rich plasma membrane to be phosphorylated in G2i 
cells. 
We confirmed these results by performing a fractionation experiment in Ci and 
G2i cells where actin was used as a cytoplasmic marker and FGFR2 as a 
membrane marker (Fig 4.10c).  A larger population of Akt was found in the 
membrane in G2i cells compared to Ci cells. This is consistent with the 
increased pool of PIP3 observed in G2i cells serving to recruit Akt.  
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Fig 4.10 Membrane localization of lipid binding Akt-PH domain is higher in 
G2i cells compared to Ci cells.a) Ci and G2i cells transfected with an empty 
mCherry vector or mCherry-Akt-PH vector were serum starved, lysed and used 
for western blot analysis where the blots were probed with the indicated 
antibodies.b) Ci and G2i cells transfected with an empty mCherry vector or 
mCherry-Akt-PH vector were serum starved and used for microscopy as 
explained in the Materials and Methods section. FGFR2-GFP was used as a 
membrane marker to show co-localization of the lipid binding PH domain on the 
membrane bound FGFR2.c) Serum starved Ci and G2i cells were fractionated 
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into membrane and cytoplasmic portions, lysed and used for western blot 
analysis then probed with the indicated antibodies. 
 
 
Akt phosphorylation is concomitant with reduced Grb2 and increased 
Plcγ1 concentrations in uterine corpus epithelial cancer (UCEC) 
According to our data depletion of Grb2, concomitant up-regulation of Plcγ1 and 
subsequent phosphorylation of Akt should be manifest in cancer. We would 
expect that cells expressing FGFR2 accompanied by low Grb2 and high Plcγ1 
concentrations would exhibit higher oncogenic prevalence. To confirm the 
physiological relevance of our observations we performed a comprehensive 
analysis using “The Cancer Genome Atlas” database.  
RPPA data on PI3K/PTEN/Akt expression and/or phosphorylation levels in 
different types of patient tumor samples were extracted. Inverse correlation 
between the Grb2 concentration and phosphorylation of Akt (on both S473 and 
T308) were observed in several tumor-types (Fig 4.11a (S473), 4.11b (T308)). 
Furthermore, pAkt was also seen in several tumor-types with high Plcγ1 
expression (Fig 4.11c (S473), 4.11d (T308)). Uterine corpus endometrial 
carcinoma (UCEC) which is one of the most common cancers of the female 
reproductive system showed a particularly strong correlation between pAkt with 
low Grb2 and high Plcγ1 concentrations. 
This is consistent with our observations in the HEK293T model cell line reported 
herein. The RPPA results for tumor types for both S473 and T308 are shown in 
Fig 4.11e, 4.11f. 
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Fig 4.11 Akt phosphorylation level is among the highest in UCEC and it 
negatively correlates with Grb2 expression but positively correlates with 
Plcγ1 expression. a),b),c),d) Data was downloaded from TCGA website for 
eleven tumor types as described in the materials and methods section. Level 3 
Illumina RNASeq versions 1 and 2  RPPA data were used for mRNA and 
protein expression level. Statistical analysis was performed in R (version 
2.14.2) where p-value > 0.05 is considered to be significant and is shown in red. 
p-value< 0.05 is shown in blue. The Spearman's rank-order correlation test was 
performed to measure the strength of the association between Grb2 mRNA and 
pS473/pT308 RPPA levels in a) and b) respectively and also between Plcγ1 
and pS473/pT308 RPPA levels in c) and d) respectively across different tumor 
types. e),f) A box-and-whisker plot was used to visualize RPPA levels across 
tumor types following TCGA database analysis.   
 
 
 
Grb2 depletion results in enhanced tumor formation in xenograft mouse 
model with increased Akt phosphorylation level 
PCi, PG2i, PPγi, Ci, G2i, and Pγi cells were used in the generation of a 
xenograft mouse model where 0.5 x 106 cells were subcutaneously injected in 
the right flank of adult female nude mice (4 mice per group). After 60 days, mice 
were subjected to MRI scanning as explained in the method section to 
determine tumor volume in every case. As can be seen in the first panel in Fig 
4.12a , which corresponds to the coronal section, mice injected with G2i cells 
showed drastic increase in tumor size and also the development of multiple 
tumors in the vicinity of the primary one compared to mice injected with Ci and 
PG2i cells. PCi injection failed to develop noticeable tumors as in the case of 
Pγi and PPγi (results not shown).  
These results are clear in the second panel and also in the third panel which 
corresponds to the axial sections. Tumor weight and volume (Fig 4.12b) are 
also higher in G2i tumors compared to Ci and PG2i tumors. This outcome is 
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consistent with the one obtained in colony formation assay where G2i cells 
were relatively unique in their ability to form multiple colonies of increased size. 
Ci and G2i tumors were used in western blot analysis as shown in Fig 4.13a. 
As expected, G2i tumors expressed a higher level of Akt phosphorylation 
compared to Ci tumors. Total Akt and actin were used as loading controls in 
both cases. 
Morphologically, the G2i tumor cells have a higher grade of malignancy than Ci 
tumor cells (Fig 4.13b). Ci tumor appears to be composed of densely cellular 
and poorly differentiated neoplastic cells that have small/minimal amount of 
eosinophilic cytoplasm and oval or pleomorphic nuclei. The nuclei have 
hyperchromatic, coarse or stippled chromatin and prominent one or two 
nucleoli. The tumor has delineated margins and is surrounded partially by a 
fibrous capsule. There is a high mitotic rate of approximately 60-70 mitotic 
figures per 400x magnification field. Numerous apoptotic cells are present. The 
tumor has a few small areas of necrosis representing approximately 5-10% of 
the entire tumor. G2i tumor is composed of similar type of neoplastic cells, but 
more anaplastic or higher degree of cellular pleomorphism. These neoplastic 
cells have lower amount of cytoplasm. The nuclei are markedly pleomorphic 
and have severely coarse, stippled or clumped hyperchromatic chromatin, and 
prominent multiple nucleoli. A similar high number of nuclear mitotic figure are 
present. There is increased number of apoptotic cells and large areas of 
necrosis affecting approximately 60-70% of the entire tumor. The margins of the 
tumor are indistinct and there is infiltration of tumor cells into the fibroadipose 
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tissue at the periphery of tumor. As shown in Fig 4.13c Ci tumor cells stained 
negative for pAkt (serine 473) antibody. There is only a minimal nonspecific 
background staining. Also, the necrotic areas of tumor have nonspecific/false 
staining. In the G2i sample, there is positive staining of these tumor cells. The 
staining is more intense in the tumor cells from the perivascular regions. 
Nonspecific/false background staining of the necrotic areas is also present.  
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Fig 4.12 Tumor formation is drastically enhanced in mice injected with 
Grb2 knockdown cells in a background of FGFR2 expression a) First panel: 
Coronal MRI images of PCi, PG2i, Ci, G2i injected mice following 60 days of 
subcutaneous injections. Arrows indicate the tumors formed. Second panel: 
Sample from each group showing absence of tumor (PCi injected mice) or 
size/number of tumors formed in every group. Third panel. Axial MRI images of 
PCi,PG2i,Ci,G2i injected mice following subcutaneous injections. Arrows 
indicate the tumors formed. b) Tumors from every group were weighed and 
averaged. Bar graphs were plotted and error bars denote standard deviation of 
the mean. Tumor volumes were calculated for mice in every group as explained 
in details in the methods section. 
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Fig 4.13 G2i cells form tumors of a higher grade of malignancy compared 
to Ci tumors and have a higher level of Akt phosphorylation a) Tumor 
sections were sonicated and proteins were extracted and used for western blot 
analysis where the blots were probed with the indicated antibodies. b) H & E 
staining of Ci and G2i tumors taken at 40x and 600x. c) pAkt staining of Ci and 
G2i tumors taken at 40x, 200x,and 400x. 
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In summary, competition between Plcγ1 and Grb2 for binding to FGFR2 
controls membrane levels of PIP2 which in turn affects the phosphatase activity 
of PTEN.Consequenly the phosphorylation statuts and activity of Akt can be 
modulated accordingly where high levels of Akt phosphorylaion is evident in G2i 
tumors (tumors formed in xenograft models following the injection of Grb2 
knockdown cells in mice). 
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Chapter Five: Discussion 
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SH3 domains of Grb2 and Plcγ1 compete for the same binding site on 
FGFR2 
 
The novel results presented in Chapter 2 represent a critical principle in 
FGFR2-dependent cancer signaling, specifically that signal transduction-
mediated oncogenic outcome can be based entirely on the competition of non-
phosphorylated ligands (namely Grb2 and Plcγ1) for a non-phosphorylated 
protein binding site.  
The measured KDs for the SH3 domains of both Grb2 and Plcγ1 binding to 
FGFR2 is similar which means that the receptor binding site could be occupied 
equally by either Grb2 or Plcγ1 under equimolar conditions.  
In normal cells the Grb2 concentration is assumed to be greater than that of 
Plcγ1 since it is a critical adaptor protein required for the activation of several 
pathways and thus under non-stimulated conditions Grb2-FGFR2 complex will 
prevail.  
This complex formation leads to the inhibition of the lipase activity of Plcγ1. 
Nevertheless, any fluctuation in protein concentrations like a decrease in Grb2 
(G2i cells) or increase in Plcγ1 and/or FGFR2 will allow the phospholipase to 
out-compete the inhibitor causing an induction of constitutive and uncontrolled 
phospholipase activity.  
Since tyrosine kinase-mediated signal transduction is typically constrained by 
stimuli mediated receptor activation/deactivation, the concentration-dependent 
activation of the lipase seems to be under much looser regulation. The 
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implications for disease can thus be mediated by protein concentration 
fluctuations (Fig 2.1). 
The described process of the SH3 domain-mediated activation of Plcγ1 can be 
considered an additional mechanism to that which occurs upon the binding of 
the lipase on pY769 following extracellular stimulation 
The dynamics of such SH3 domain mediated basal state binding to the C-
terminus of FGFR2 can possibly be dependent on a conformational change in 
the structure of the lipase mimicking the previously well-established activation 
caused by NSH2 domain binding. Plcγ1SH3 domain forms an interface with the 
CSH2-SH3 linker region (residues 759-791) possibly playing a significant role in 
stabilizing the auto-inhibited state (31). This interaction can in part occlude the 
canonical proline-rich motif-binding site on Plcγ1SH3 thus basal state binding to 
FGFR2 will destabilize the auto-inhibitory potential of the CSH2 domain by 
disrupting the intramolecular SH3 interaction.  
Also, it has been previously reported that isolation of the lipase SH3 domain 
has negligible effect on the enzymatic activity (16), however deletion of the 
domain does not replicate the effect of binding to FGFR2 and the consequent 
conformational change. Interestingly, the CSH2 domain has been shown to 
have some affinity to the CSH2-SH3 linker region in a phosphorylation 
independent manner (31). Thus, the possible conformational perturbation 
accompanying the Plcγ1SH3-FGFR2 interaction would expose the CSH2-SH3 
linker region and the interaction of CSH2 with the linker will serve to reverse the 
auto-inhibition. This is plausible especially after taking into consideration a 
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similar mechanism where the split PH domain of Plcγ2 is critical and sufficient 
for the activation of the lipase (60-64). 
 
Grb2 and Plcγ1 competition controls lipase mediated cell migration and 
invasion 
Grb2 binds and interacts with several proteins thus depleting it would have 
significant effects that could affect Plcγ1 activity and/or phospholipid turnover. 
In this case cellular migratory and invasive potential could be influenced by the 
fluctuation of protein concentrations via a mechanism independent of the one 
described here. However, there are many critical points that should be taken 
into consideration before making such an assumption. So far, this project has 
provided evidence that the adaptor protein directly affects Plcγ1 lipase activity 
by the following:  
1) Grb2 and Plcγ1 compete for a binding site on FGFR2. When this receptor is 
absent, like in HEK 293T parental cell line which express negligible levels of 
FGFR2, the constitutive phospholipase activity is absent. 
2) Depletion (via knockdown) or inhibition (via U0122) of Plcγ1 eliminates the 
cellular effects observed, while knocking in the lipase rescues the phenotype. 
3) Plcγ1 activity in other signaling pathways is evident only under conditions of 
stimulation dependent receptor up-regulation. Here, FGFR2 was left un-
stimulated, and therefore was incapable of phosphorylating the lipase. 
4) Both Grb2 and Plcγ1 bind to the protein Sos which initiates and activates the 
downstream MAPK pathway (65). Knocking down Grb2 could result in the 
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observed phenotype by increasing the influence of the lipase on MAPK 
signaling. This hypothesis is unlikely since MAPK response is absent on Grb2 
knock down (2).  
5) Plcγ1 can get activated by non tyrosine kinases (NTKs). When Grb2 is 
depleted (via knockdown), NTKs like Src Family kinases (SFKs) could become 
up regulated and hence activate the lipase. In this case, the cells are under 
basal conditions and NTKs are up regulated solely on stimulation by activated 
receptors thus activity toward the lipase is improbable. 
6) Grb2 mediates the downstream phosphorylation of PIP2 to PIP3 via PI3K. So, 
in the absence of the former there can be an increase in the relative 
concentration of PIP2. But since there is an obvious depletion of PIP2 in G2i 
cells and a simultaneous increase in intracellular calcium levels, down-
regulation of PI3K activity cannot justify the observed phenotype. 
It is also critical to analyze the reasons behind the evolution of the Plcγ1SH3 
domain mediated constitutive interaction and activation of the lipase alongside 
the previously well-established SH2 binding to activated FGFR2. The SH3- 
dependent activation mechanism is highly plausible since it is based on the 
concentration of the lipase where control of the intracellular level is a 
“housekeeping” activity critical for the maintenance of membrane constitution 
homeostasis and the subsequent intracellular calcium mobilization.  
For example, there is growing evidence from a number of tissues like vascular 
smooth muscle, that tyrosine phosphorylation is crucial yet inadequate to fully 
activate the lipase. It might instead be critical for the translocation of Plcγ1 from 
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the cytosol to the actin cytoskeleton (66). Also, it has been shown that in 
Xenopus oocytes the binding of the SH3 domain to Sos induces pY783-
independent background phospholipase activity (67).  
It is important to note that controlling intracellular signaling via the law of mass 
action makes the cells more sensitive to fluctuations in protein concentrations. 
As Plcγ1 expression level increases, it can contribute to oncogenesis and 
metastasis by outcompeting Grb2 for the FGFR2 binding site. For example, it 
has been previously shown that over-expression of Plcγ1 induces 
transformation of NIH3T3 fibroblasts (68,69).  
Plcγ1 expression is also significantly high in colorectal cancer and colon 
carcinoma cell lines compared with normal tissue (70). Additionally, several 
breast carcinoma tissues have an elevated level of expression of non-
phosphorylated Plcγ1 (71). For instance, certain breast cancer cell lines like 
MDA-468 have high levels of membrane-associated non-phosphorylated Plcγ1 
before stimulation; i.e. 69% of Plcγ1 is membrane bound under basal non-
stimulated conditions compared to 4% in MCF-7 cells (72). Those cells also 
express high levels of FGFR2 (73) and upon epidermal growth factor (EGF) 
stimulation there is an insignificant increase in Plcγ1 membrane localization. 
Therefore, in MDA-468 metastatic breast cancer cell line it is considered 
possible that there is an up-regulation in the activity of the lipase upon receptor 
mediated recruitment to the membrane. 
A similar effect on oncogenesis and metastatic outcome can be observed in the 
context of reduced cellular Grb2 concentration. By examining the data from 
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ovarian cancer patient samples, there was a clear relationship between reduced 
levels of Grb2 expression and metastasis. In those samples there was a 
concomitant increase in the expression level of both Plcγ1 and FGFR2.  
Thus, Grb2-mediated control of FGFR2 activity is imperative in maintaining 
cellular homeostasis under basal non-stimulated conditions. Nevertheless, 
FGFR2-Grb2 heterotetrameric complex formation through CSH3 interaction, 
which has a weak affinity to the receptor, can leave the complex open to 
competing SH3 domain binding which might result in an oncogenic outcome. 
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PTEN-mediated activation of Akt is dictated by Grb2 expression levels 
 
Plcγ1 has been previously shown to be up regulated upon Grb2 depletion in a 
background of FGFR2 expression (59). Here the competition between Grb2 and 
Plcγ1 for binding to FGFR2 in a concentration dependent manner appears to 
cause a perturbation of membrane lipid concentration balance. This effect tends 
to modulate PTEN activity and consequently Akt membrane localization, 
phosphorylation and activation.  
Thus, the novel results presented in Chapter 4 emphasize the importance of 
Grb2-Plcγ1 competition in controlling the level of PIP2 critical for PTEN’s 
association with the membrane. Previous studies have revealed that a 
truncated version of this tumor suppressor gene missing the PIP2 binding motif 
failed to associate with the membrane (74). PIP2 has also been shown to be 
required for the induction of a conformational change in the structure of PTEN 
by binding to the N-terminal domain of the latter. Even mutations in the N-
terminus of PTEN have been shown to severely reduce the activity of PTEN by 
possibly blocking the protein from binding PIP2 (75). Thus PTEN is suggested to 
remain cytosolic in an inactive conformation where the catalytic domain is 
masked by PIP2-binding domain. When PTEN binds on PIP2 on the membrane 
a conformational change is induced that activates the phosphatase activity of 
PTEN (76,77). 
These studies provide strong in vitro and cell biological proof yet are lacking to 
a certain level in the conditions and functional effects of PTEN/PIP2 interaction.  
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Chapter 4 presents substantial evidence supporting the importance of PIP2 in 
regulating PTEN activity in vivo and in vitro. It also shows how fluctuations in 
the concentration of two non-phosphorylated proteins interacting with a receptor 
via their SH3 domains can have drastic effect not only on migration, invasion, 
and possibly metastasis but also on tumor development by controlling cellular 
proliferation through PTEN, which in turn modulates Akt activity (Fig 5.1). One 
can thus argue in favor of the importance of this mechanism where cellular PIP2 
concentration regulates PTEN activity and a decrease in the level of this lipid 
leads to loss of PTEN function mimicking the effects of tumor-derived mutations 
identified in PIP2 binding motif—such as K13E, found in glioblastoma and 
endometrial carcinoma, and S10N, found in lymphoma (78,79). 
Akt (the read out for PTEN activity) has a higher level of membrane localization, 
and phosphorylation under conditions where Plcγ1 outcompetes Grb2 for 
FGFR2 binding or upon PTEN inhibition like in G2i cells or SF1670 treated cells 
respectively. Also, it is important to note that under in vivo or in vitro conditions 
(cell lysate based assays and in vitro reconstitution assays) where Plcγ1 
replaces Grb2 on FGFR2 via its SH3 domain, PTEN is inactive. This is shown 
to be a direct effect of the depletion of PIP2 required for the activity and 
membrane localization of the phosphatase. Hence the end point of fluctuation of 
Plcγ1/Grb2 concentration in cells and possibly tumors like UCEC is the 
modulation of Akt activity via PTEN where Akt shows a negative correlation with 
Grb2 and a simultaneous positive correlation with Plcγ1. 
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As for the effect of such a mechanism on cellular function, the experiments are 
based on the concept that in the multistep metastatic process, cancer cells at a 
certain stage need to grow in an anchorage-independent manner and thus 
survive without interacting with the cell’s substratum. Akt regulates such a 
process where the inhibition of the Akt pathway leads to the formation of fewer 
colonies in soft agar (21). 
Colony formation is enhanced upon knocking down Grb2 but not Plcγ1 in a 
background of FGFR2 expression compared to Ci/Pγi cells with FGFR2 and 
endogenous levels of Grb2 and parental cells that express negligible levels of 
FGFR2. Also, inhibiting PTEN increases the number of colonies formed, which 
is an opposite effect to that observed with PI3K or Plcγ1 inhibition.  
The soft agar assay results were validated in a xenograft mouse model, where 
tumor formation seems to be enhanced in G2i cells compared to parental cells 
,with negligible levels of FGFR2, and Ci cells. G2i tumor cells express higher 
level of phosphorylated Akt (western blot and IHC results) compared to Ci cells. 
Thus, the competition between Grb2 and Plcγ1 can be a critical factor in Akt 
mediated tumor formation by controlling the levels of PTEN activation. 
All of this, along with the effect seen upon inhibiting Akt, leads to the conclusion 
that cellular proliferation is a direct result of Akt protein activation. These 
observations are of great significance since they reveal the importance of Grb2 
as a global regulator protein affecting several pathways. Also, they show that in 
cancer development protein-protein competition could be as important as 
genetic aberration and fluctuations in protein expression levels.  
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Thus, SH3 domains, which have received little attention especially under non-
stimulated conditions, have proven to be essential for normal cell function 
where any shift in their concentration can tip the balance towards uncontrolled 
cell proliferation and invasion. 
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Fig 5.1 Grb2-Plcγ1 competition for binding to the C-terminus of FGFR2 
regulates cell proliferation, migration and invasion.a) (1)Dimeric Grb2 binds 
to two molecules of FGFR2 forming a heterotetramer. (2) Grb2 binding to 
FGFR2 blocks the access of Plcγ1 to the receptor. (3) Steady state levels of 
PI3K and PTEN activity and lack of activity of Plcγ1 maintains a normally low 
level of PIP3. (4) Akt, which binds on PIP3 to get phosphorylated and 
subsequently activated, cannot localize on the membrane efficiently. b) (1) 
When the cellular level of Plcγ1 increases compared to Grb2, it replaces the 
latter on FGFR2. (2) Receptor binding leads to the constitutive activation of 
Plcγ1 lipase activity thus hydrolyzing PIP2 to IP3 and DAG depleting the 
membrane of PIP2. (3) PIP2 is required for the stabilization and membrane 
localization of PTEN thus PTEN activity is severely dampened while PI3K has a 
steady state activity. Lack of activity of PTEN, which dephosphorylates PIP3 
back to PIP2, causes a buildup of PIP3. (4) Accumulation of PIP3 induces a 
surge in the activity of Akt following its membrane localization. (5) Increase in 
Plcγ1 and Akt activity amplifies cellular proliferation, migration and invasive 
potential. 
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Chapter Six: Conclusion, Significance and Future 
Directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   169	  
Grb2 and Plcγ1 SH3 domain mediated competition for the same binding 
site on FGFR2 regulates cell migration and invasion 
 
Grb2-mediated control of FGFR2 activity is critical in maintaining cellular 
homeostasis under basal non-stimulated conditions. This is achieved by the 
formation of a heterotetrameric complex through Grb2CSH3 interactions (2). 
Nonetheless the modest affinity of this complex leaves it vulnerable to 
competing SH3 domain binding. Thus, under appropriate cellular conditions 
Plcγ1 replaces Grb2 on FGFR2. The lipase in this case becomes constitutively 
active leading to the depletion of PIP2 and a surge in intracellular calcium level 
(59).  
This concept is of great significance since it proposes a mechanism for a 
phosphorylation-independent control of cell membrane constituency and 
calcium flux leading to the phenotypic response of increased cell motility, which 
has the potential to lead to metastasis in cancer cells.  
In order to establish the solid connection between the intracellular balance 
between Grb2 and Plcγ1 and metastasis, Ci, G2i and Pγi cells (containing a 
luciferase vector to monitor metastasis via imaging and MRI) need to be 
injected in an animal model (like nude mice). In this case, it is possible that G2i 
cells will show a higher level of metastatic potential compared to Ci cells. If 
Plcγ1 is indeed responsible for the metastatic outcome then knocking it down 
will inhibit the metastatic process. 
Thus, dependence of this phenotype on the relative intracellular concentrations 
of Grb2 and Plcγ1 in a FGFR2 background suggests that the expression levels 
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of these proteins could provide reliable markers for metastatic outcome in 
patients. This is critical when studying and testing drugs that aim at targeting 
Grb2 (80-87) since the factor of Grb2/Plcγ1/FGFR2 concentration should be 
taken into consideration or else the metastatic potential of the primary tumor will 
be enhanced by shifting the balance towards Plcγ1 and allowing for its 
constitutive binding to FGFR2 and the consequent uncontrollable up-regulation 
of its activity. 
Also, since Grb2 in this case is acting as a controlling factor that to some extent 
reduces cell migration and invasion, then manipulating its level of expression 
can potentially be of great significance in inhibiting metastasis. This rationale 
can be employed in performing a database search to further investigate the 
Grb2 specific micro RNAs (miRNA) and their role in silencing Grb2 gene 
expression.  
Prospective candidates and specifically in ovarian cancer can be considered 
oncogenic and targeting them in cell lines to begin with can open the door for 
the investigation of a novel therapeutic cancer type dependent anti-metastatic 
agent. 
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PTEN-mediated activation of Akt is dictated by Grb2 expression levels 
 
It appears that through the resultant perturbation of the phospholipid 
constitution of the plasma membrane, depletion of Grb2 has an oncogenic 
outcome. In this work we investigate the combined effects of enzyme-regulated 
concentrations of PIP2 and PIP3 on Akt signal transduction and demonstrate 
that these can be directly linked to cellular Grb2 concentration.  
Thus, this work provides a novel entrée in understanding the conditions 
triggering an anomalous Akt response. This provides groundwork for future 
studies in animal models to show that fluctuating the concentration of Grb2 SH3 
domain instead of full length protein (as shown in this work) can control for 
Plcγ1-FGFR2 association and the subsequent effect on PIP2 level. This can be 
the basis of therapeutic agents that mitigate the aberrant Akt oncogenic 
signaling pathway that drives many cancers, and can become an alternative or 
adjunctive (secondary) approach to the use of numerous kinase inhibitors, 
many of which are toxic, and can be highly non-specific when used to dampen 
the aberrant hyperactivation of Akt. It can also be exploited as a diagnostic tool 
especially that it is becoming more crucial to develop methods to identify those 
patients with tumors driven by Akt-based molecular abnormalities (88,89) or 
when other means of Akt pathway inhibition can be used to enhance the effect 
of radiation or traditional chemotherapeutic drugs (90-95).  
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Taken together, the current findings offer a novel concept namely:“The role of 
SH3 domains competition in tumor development and metastasis” that has the 
potential to become the foundation of several intervention strategies in PTEN-
mediated disease treatment modalities like the pharmacotherapy of cancer. 
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